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Benefits of Nitric Oxide Cues to Matrix Synthesis by Healthy and Aneurysmal 
Human Smooth Muscle Cells within 3D Cocultures 
 
PHILLIP SIMMERS 
 
ABSTRACT 
Vascular diseases such as atherosclerosis and aneurysms are characterized by the 
over-proliferation and migration of aortic smooth muscle cells (SMCs), and degradation 
of extracellular matrix (ECM) within the vessel wall, leading to compromise in cell-cell 
and cell-matrix signaling pathways. Recent tissue engineering approaches to regulate 
SMC over-proliferation and enhance healthy ECM synthesis showed promise, but 
resulted in low crosslinking efficiency and matrix deposition yields. In this study, the 
benefits of exogenous nitric oxide cues, delivered from S-Nitrosoglutathione (GSNO), to 
cell proliferation and matrix deposition by adult human aortic SMCs (HA-SMCs) within 
3D biomimetic cultures have been explored.  The first experiment utilized a microfluidic 
platform with two adjacent, permeable 3D culture chambers, to enable paracrine 
signaling between vascular cell cocultures. Healthy HA-SMCs were cultured in these 
devices within 3D collagen hydrogels, either alone or in the presence of human aortic 
endothelial cell (HA-ECs) cocultures, and exogenously supplemented with varying 
GSNO dosages (0-100 nM) for 21 days.  Results showed that EC cocultures stimulated 
SMC proliferation within GSNO-free cultures. However, with increasing GSNO 
concentration, HA-SMC proliferation decreased in the presence or absence of EC 
cocultures, while HA-EC proliferation increased. GSNO (100 nM) significantly enhanced 
the total protein amount synthesized by HA-SMCs, in the presence or absence of EC 
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cocultures, while lower dosages (1-10 nM) offered marginal benefits. On a per cell basis, 
multi-fold increases in the synthesis and deposition of elastin, glycosaminoglycans, 
hyaluronic acid and lysyl oxidase crosslinking enzyme (LOX) were noted at higher 
GSNO dosages, and coculturing with ECs significantly furthered these trends. The matrix 
yields of these proteins reached almost 40 - 51 % within selective cocultures receiving 
GSNO. Similar increases in TIMP-1 and MMP-9 levels were noted within cocultures 
with increasing GSNO dosages, although MMP-2 levels remained attenuated. These 
quantitative assay data were strongly supported by immunofluorescence images under 
respective conditions.  Based on the optimized dosage (100 nM) deduced from first 
experiment, we tested the utility of NO cues within diseased HA-SMC (derived from 
aneurysmal human aortic segment) cultures, under both 2D and 3D culture conditions.  
Results showed that cell proliferation was higher on 2D substrates compared to that 
within 3D cultures. In accordance to the trends noted within healthy SMC cultures, there 
was a decrease in cell proliferation in both 2D and 3D, with increasing GSNO dose.  
Similarly, the presence of GSNO stimulated elastin, glycosaminoglycans, hyaluronic 
acid, lysyl oxidase crosslinking enzyme (LOX), MMP-2, 9 and TIMP-1 synthesis and 
release by aneurysmal SMCs, although the matrix deposition levels were lower compared 
to their healthy counterparts.  Both experiments results attest to the tremendous benefits 
of delivering nitric oxide cues to suppress SMC proliferation and promote robust ECM 
synthesis and deposition by adult human SMCs, with significant applications in tissue 
engineering, biomaterial scaffold development, and drug delivery. 
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CHAPTER I 
 
BACKGROUND 
 
1.1. Vascular tissue organization 
Excluding the capillaries and the venules of the peripheral circulation system, all 
blood vessel walls are composed of three distinct layers:  tunica intima, tunica media, and 
the tunica adventitia (Fig. 1.1).  The tunica intima is the inner most layer, which is 
composed of endothelium and a connective tissue basement membrane.  Following the 
basement membrane is a layer of smooth muscle and connective tissue called the lamina 
propria.  Encapsulating the lamina propria is the internal elastic membrane, which consist 
primarily of elastic fibers.  Following the tunica intima is the tunica media which is a 
layer of smooth muscle cells with a circular arrangement.  This is the layer that allows for 
the movement of blood through the vessel through contraction and relaxation.  Just like 
the outer layer of the tunica intima the tunica media has an elastic membrane that 
separates it from the tunica adventitia.  The last layer, or the tunica adventitia, is 
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composed of dense connective tissue near the tunica media and gradually transitions to 
loose connective tissue in order to merge the blood vessels with the surrounding tissue
1
.     
 
Figure 1.1 The layers of the blood vessel
2
. 
 
1.2. Vascular extracellular matrix  
Vascular tissue as described previously is broken up into three different layers.  The 
composition of the extracellular matrix adds to the overall properties of the individual 
layers and is dependent on the cell phenotype located in the layer.  The tunica intima 
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connective tissue is very thin and primarily made of endothelial cells with little matrix 
while the smooth muscle cells in the tunica media deposit and upkeep the internal and 
external elastic lamina which are responsible for the pulsatile stretching forces 
experienced in the arterial walls.  Lastly, the fibroblast located in the tunica adventitia 
deposit much of the collagen found in the vascular tissue
1
.  The description of the most 
important extracellular matrix proteins of the vascular tissue can be found below. 
 
1.2.1. Collagen 
The most abundant protein found in ECM is collagen which plays an integral role in 
providing both support and tensile strength to the vascular tissue.  Collagen exists in 
many different types in the human body, but the most common one found in vascular 
tissue is type I, which comprises 80% of the total collagen found.  Type III makes up 
12% of collagen found with the last 8% being composed of trace concentrations of types 
IV, V, and VI collagen.  The structure of all collagen is that of a triple helix that are 
constructed with α-chains.  It is the altercations in the α-chains that result in the formation 
of different collagen types.  The glue that holds the triple helix structure of collagen 
together is the chemical bonds between the hydroxylated amino acids of proline and 
lysine.  The fibrous nature of collagen I, III, and V aggregates together to create larger 
fibers.  These fibers are the main structural support of the tissue and connect main 
vascular tissue components
3–8
.  Cells are able to migrate along the collagen fiber through 
the use of fibronectin
9
. 
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1.2.2. Glycosaminoglycans  
Glycosaminoglycans (GAGs) are anionic polysaccharides with hydrophilic chains 
that have many disaccharide units.  There are two main types of GAGs, those with and 
those without sulfated groups attached to the sugar molecules.  Further categorization of 
GAGs focuses not only on sulfate groups, but the types of sugars and their bonding 
characteristics.  The four main groups of GAGs are; hyaluronan, chondroitin sulfate, 
heparin sulfate, and keratin sulfate.  The only GAG that is non-sulfated in its disaccharide 
unit is the hyaluronic acid (HA) molecules
4,6,10
.   
GAGs are known mainly for their hydrophilic properties that allow them to expand 
forming hydrogels.  This occurs by the large negative charges on their surface, which 
attract many cations that are osmotically active, to successfully attract water into the 
GAG matrix.  Mechanically, GAGs are resistant to compression and thus help vascular 
tissue to keep its physical integrity from exterior forces.  Also sulfated GAGs are able to 
covalently bond to other proteins, which form structures commonly known are 
proteoglycans
9
. 
Proteoglycans perform a wide range of functions for the surrounding cells.  One 
proteoglycan unit consists of a protein core attached to covalently bonded GAG chains.   
They provide the necessary hydrated space around cells, regulate the passage of certain 
molecules, bind to growth factors and other signaling proteins for signal transduction, and 
guide cell migration through the extracellular matrix
9
.  
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1.2.3. Elastin  
One of the most essential ECM protein of the vascular system, elastin provides the 
necessary elastic properties allowing for blood to be properly pumped through the 
circulatory system by bearing the mechanical pressure applied to the tissue during the 
cardiac cycle
9
.  Elastin is formed when soluble monomers, tropoelastin and fibrillin, are 
cross-linked by the enzyme lysyl oxidase (LOX) forming an insoluble protein.  Fibrillin 
is a glycoprotein that is essential in the formation of elastic fibers.  Each type of fibrillin 
performs a different function in the formation of fibers with fibrillin-I performing the 
most important function in elastin formation.  Fibrillin-1 serves as a structure glue 
component of calcium by binding microfibrils (i.e. tropoelastin).  The microfibrils then 
provide the structural integrity of tissues as well regulation of cytokines through the 
sequestration of molecules.   The majority of elastin is synthesized during the neonatal 
developing stages, or the period from birth to one month old, and there is a significant 
decrease in the synthesis of mature matrix elastin in adults.  Elastin is not only important 
due to the mechanical properties it contributes to the overall tissue but it has been also 
noted to regulate SMC proliferation and morphology
11–14
 .   
 
1.2.4. Lysyl oxidases 
Lysyl oxidases (LOX) are an extracellular copper enzyme that can catalyze aldehydes 
from lysine residues in tropocollagen and tropoelastin.  The aldehydes are highly reactive 
and thus spontaneously react with lysyl oxidase derived aldehyde residues resulting in the 
cross-linking of collagen and elastin, which successfully stabilizes the collagen fibrils as 
well as develops mature matrix elastin
15
 .  
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1.2.5. Matrix metalloproteinases and their inhibitors  
Matrix metalloproteinases (MMPs) are naturally occurring extracellular proteolytic 
enzymes that degrade ECM proteins.  During periods of inflammation these enzymes are 
upregulated in order to destroy the ECM to make room for inflammatory cells.  MMPs 
are able to break down much of the ECM proteins by attacking the cross-linkers that hold 
many of the proteins together.  To ensure that MMPs are not left unchecked, the synthesis 
of tissue inhibitors of metalloproteinases (TIMPs) is necessary for protection of non-
damaged tissue.  TIMPs are protease–specific and bind to activated proteases during the 
inflammatory phase restricting the activity of MMPs
6,8
 .  Thus, a careful balance of both 
TIMP and MMP expression is needed to properly reorganize vascular ECM.   
 
1.3. Vascular aneurysm 
When vascular elastin is congenitally malformed, or damaged by local injury, or 
degraded by acquired diseases, it severely compromises vessel integrity, disrupts cellular 
signaling pathways, initiates inflammation, and weakens vessel wall
16
.  This can lead to 
an aneurysm or the ballooning/dilation of an artery.  Aneurysms can come in two general 
shapes as seen in Fig.1.2.  The first is the formation of a pouch or sac on one side of the 
blood vessel wall and is commonly known as a saccular aneurysm.  The second is called 
the fusiform aneurysm and is commonly defined as the dilation of the artery in all 
directions
17
.  Hypertension of this area can lead to a burst in the vessel and thus 
hemorrhage of blood into the surrounding tissue
1
.  Under such non-healthy conditions, 
elastin gene expression is down-regulated, and the mature elastin is degraded by MMPs 
and macrophage-derived elastases (cytokines, interleukins) into soluble peptides, which 
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furthermore interrupts elastin-SMC signaling pathways
18–23
. Such elastin disruption 
encourages SMC hyper-proliferation and medial thickening, leading to reduced arterial 
compliance, hypertension and aneurysm of the vessel
24–29
. The ability for vascular tissues 
to self-repair is hampered by their inherently complex matrix structure and compromised 
cell-signaling pathways.   
The development of aneurysms might be one of the most prevalent cardiovascular 
conditions, possibly affecting up to 90% of people
30
.  Due to the possibility of living with 
an aneurysm without it rupturing, as well as poor diagnosing methods, many conditions 
go untreated creating for an even larger risk.  Besides, understanding the mechanisms 
leading to hypertension remain broadly unidentified
31
.  As explained previously, the 
mechanical properties of cardiac tissue are obtained from the ECM, mainly the elastin 
and collagen fibers
32
.  Since elastin functions mainly at lower pressures than collagen, the 
hypertension of vessel walls can be accounted for the degeneration of elastin, leading to 
many cardiac diseases
31
.   
Abdominal aortic aneurysms (AAA) is the extension of an abdominal aortic section, 
usually developing over several years, and is currently the 10
th
 leading cause of death in 
the United States, killing roughly 15,000 people annually
33
.  As stated previously, many 
of these cases are left undiagnosed and untreated, which results in a high mortality rate 
~75-90%
34
.  Many of the cases discovered are done so by accident during routine 
physical or radiographic exams on an unrelated symptom
34
 and only six countries in the 
world offer a clinical screening procedure standard
35
.  Other than the risk of rupture, the 
disruption of flow in the aneurysmal blood vessel can cause a multitude of symptoms 
depending on the type and location of the aneurysm, including; headaches, blurred or 
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double vision, weakness or numbness.  The disruption of flow has been shown to change 
its direction to an anterior pathway moving along the proximal wall of the aneurysm 
creating a vortex
36
.     
  
Figure 1.2 Different types of aneurysm formations (A) saccular and (B) fusiform
17
. 
 
1.4. Approaches for aneurysm treatment 
As mentioned previously, early diagnosis of an aneurysm rarely occurs due to the 
lack of symptoms paired with the fact that many symptoms are not exclusive to 
aneurysms.  The lack of early detection can lead to rupture of the aneurysm and 
depending on the severity of the hemorrhage death may result.  The discovery a 
throbbing mass or the abnormal sound of rushing blood flow during a routine physical 
examinations can lead to further procedures including ultrasound, computed tomography 
A B 
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scan (CT), magnetic resonance imaging (MRI), or an angiography which will properly 
show the size and location of the aneurysm.  Following the diagnosis of an aneurysm 
doctors will determine if surgical, pharmacological, or a mixture of both is best for the 
treatment.  Treatment can also be in the form of altering patient behavioral factors which 
include the elimination of stressful situations, physical labor, smoking and unhealthy 
foods.   
 
1.4.1. Surgical and Pharmaceutical approaches for aneurysm treatment   
As described in the History of Aneurysms by W. E. Stehbens, treatment of aneurysms 
dates all the way back to the fourteenth century B.C. to the time of the Egyptians
37
.  
Treatment of aneurysms was first noted in 1817, when William and John Hunter 
performed the first ligation of an aneurysm
38
. The procedures evolved when the 
revolutionary surgical technique of endoaneurysmorrhaphy was developed in 1888 by 
Rudolf Matas
39
.  In endoaneurysmorrhaphy the aneurysm is opened and then collapsed 
on itself through a series of folding to return the lumen of the blood vessel to is normal 
size and then sutured back together.   
In the 1940’s, advances in the treatment of congenital heart surgery lead to many of 
the modern surgical treatments of aneurysms.  Here a ruptured aneurysm was first 
patched successfully utilizing a pectoralis muscle patch by Dr. Denton Cooley and Grant 
Ward
40
.  This experience was vital for Dr. Cooley (along with Dr. Michael DeBakey) as 
he would later develop the tangential excision and lateral aortorrhaphy, which is the 
clamping of a saccular aneurysm at its neck and then removing the ballooned portion of 
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the artery
41
.  Following their innovative treatment method Dr. Cooley and DeBakey were 
able to refine and apply the use of homografts in many new areas
41–47
.   
The next chapter of surgical treatments for aneurysms was started by Dr. Cooley in 
1963 when he founded the Texas Heart Institute
40
.  The Texas Heart Institute has 
decreased surgical mortality from 50% to 10% by modifying the Bentall and Cabrol 
procedure as well as perfecting bypass surgeries
48,49
.  Lastly in 1981, Dr. Cooley 
innovative thinking led to the preparation of woven Dacron grafts, which he helped 
develop in 1978
50, by soaking them in the patient’s own plasma and then autoclaved it 
which sealed the interstices of the graft with the coagulated protein.  By doing this Dr. 
Cooley was able to reduce the post-surgery bleeding as well as start a standard for 
manufacturing of grafts today
49,51
.          
Besides open surgery techniques as described above, some aneurysms are able to be 
treated through a minimally invasive endovascular method.  Two of the most common 
are stent graft repair and coil filling systems
52,53
.  Both of these methods access the 
cardiovascular systems from a peripheral artery, and the most widely used in clinical 
settings currently.  In the stent method the stent is put into place by a catheter and when 
in place, expands which allows blood to safely flow through and prevent any further 
damage to the aneurysm.  As for the coil systems, they are utilized predominately in 
saccular aneurysms located in the brain due to the difficulty in performing open surgery.  
Similar to the stent, coil systems are loaded into a catheter and directed to the aneurysm 
site where they are deployed successfully filling up the ballooned area and sealing it from 
the artery.      
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In conjunction to surgical treatment route, pharmaceutical options are available. 
Medications (statins) can be used to combat a patient’s high level of cholesterol which 
leads to an increase risk in atherosclerosis (a leading cause of aneurysms).  Statins can 
block the enzymes necessary for the production of cholesterol, thus reducing the levels of 
cholesterol in the blood.  Other drugs such as fibric acid derivatives, bile acid 
sequestrates, or nicotinic acid can also be used to control the cholesterol levels in the 
blood
54
.  For treatment in patients already diagnosed with an aneurysm, beta-blockers are 
commonly prescribed as they can lower heart rate, and consequently the volume of blood 
pumped which ultimately lowers the blood pressure
55
.        
 
1.5. Tissue engineering approaches for aneurysm treatment  
Tissue engineering is one avenue which within the last decade has made major strides 
in alleviating and identifying vascular aneurysms.  Specifically improved 
biocompatibility of graft materials as well as cell delivery techniques for repair and 
regeneration of many cardiac diseases are one of several advances within the field that 
may one day lead to total vascular replacement; however these types of vascular conduits 
are limited by their dimensions, composition, and host response. The first tissue 
engineered vessel was created in 1986 by Weinberg and Bell
56
 when they cultured bovine 
endothelial cells with smooth muscle cells and fibroblast in artificial blood vessels that 
had multiple layers of collagen and a Dacron mesh
57
.  Culturing of the smooth muscle 
cells and fibroblast in the presence of vitamin C created an extracellular matrix that 
mimicked nearly to the in vivo characteristics
58
. Recently, several groups have attempted 
to utilize are ePTFE, Dacron, and polyurethanes for total vascular replacement but have 
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been unable to fully overcome host immune reaction
59
. Minimization of this 
immunogenic response can be achieved through surface treatment of the material using 
proteins, cells, and other polymers
60–62
 which control the formation of thrombosis as well 
as hyperplasia within implanted grafts. Still the porous nature of these constructs allows 
for the diffusion of certain element into surrounding tissue. Lastly, Cambell et al. showed 
that when silastic tubing was inserted into the peritoneal cavity of rats and rabbits that it 
would cover the tubes with layers of myofibroblasts, a collagen matrix as well as a 
monolayer of mesothelial cells due to the inflammatory reaction.  Once removed and 
turned inside out, the structure of the vessel mirrored that of normal tissue
63
.  
Another approach beside synthetic constructs is the use of acellular extracellular 
scaffolds formed from dehydrated mammalian tissue which can then be wrapped around 
a cylindrical mandril which gives it a tubular shape.   Smooth muscle cells obtained from 
stem sources (embryonic, umbilical, and mesenchymal) can then be inserted into these 
lumens to form the vascular media.  Finally after a week in a bioreactor or other growth 
stimulating conditions, these types of scaffolds can be implanted into host tissue and 
tested for viability
57
.   Similarly, other groups have utilized a pulsatile flow in their 
scaffold design to help mature the tissues of their artificially constructed graphs to aid in 
their mechanical properties, specifically increased smooth muscle cell density, collagen 
density. One group reported on the addition of aortic smooth muscle cells placed in a 
silicone tube for 8 weeks with media pumped through at 165 beats per minute and 5% 
radial expansion
64
. In general, total vascular replacement is a promising option for those 
diagnosed with aneurysms; however currently due to the infancy of the field these 
approaches are not yet suitable for human trials. 
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1.6. Role of nitric oxide 
Nitric oxide (NO) is an important signaling molecule that has a wide array of 
biological applications.  NO is a small and relatively stable free-radical gas that readily 
diffuses into cells and interacts with molecular targets
65
.  For the purpose of this thesis 
the studies of nitric oxide in cardiac tissue have been reviewed and their overall findings 
and scope of the experiments performed are mentioned in this section.  
As discovered by Moncada et al., NO is synthesized from L-arginine substrate
66
 and 
inhibited by N
G
-monomethyl-L-arginine
67
.  This group also discovered that the NO 
pathway existed in multiple tissues showing that NO is used in a wide range of cellular 
functions and communication
68–70
.  They also claim that NO is an important regulator in 
blood pressure, platelet activation, as well as neurotransmission
71,72
.        
The work on the effects of NO on matrix synthesis ability by human vascular cells is 
lacking, but there has been work reported on vascular cells in other organisms. For 
example the administration of NO substrate was shown to suppress the induced 
pulmonary vascular disease in rats as well as eNOS
+
 mice that exhibited increased 
pulmonary hypertension and vascular disease caused by chronic hypoxia
72,73
.  This study 
shows that in rats that were treated with NO inhalation both reduced pulmonary vascular 
resistance as well as artery pressure by successfully dilating pulmonary vascular tissue.  
This shows that in the absence of NO leads to vasoconstriction and hypertension leading 
to many vascular diseases
73
 as well as a decreased inflammatory response
72
.  A similar 
study utilizing chick aortic SMCs show that the delivery of NO inhibits the proliferation 
of the cells and stimulates the expression of tropoelastin and LOX mRNA
74
.   These 
studies give enough support to the possibility of utilizing exogenously delivered NO to 
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activate SMCs enzyme release, upregulate elastin synthesis and crosslinking through 
LOX upregulation, and return to normal homeostasis in diseased tissues. 
The experiments described in this thesis utilize S-Nitrosoglutathione (GSNO) as a 
NO donor (Fig. 1.3).  It has been previously found that the formation and decay of low 
molecular weight S- nitrosothiols (such as GSNO) may represent a mechanism for the 
storage or transport of NO
75,76
.  Besides GSNO, other S-nitrosothiols include S-
nitrosocysteine (CySNO) and S-nitroso-N-acetyl-DL-penicillamine (SNAP).  GSNO is a 
preferred choice because it can be naturally occurring within the cell cytoplasm, has a 
low molecular weight of 336.32 (which allows for rapid diffusion across a scaffold), and 
possesses many different documented benefits to smooth muscle tissue such as protection 
against ischemic myocardium by increasing perfusion
77
.  The decomposition of the S- 
nitrosothiols, mainly the hemolytic cleavage of the S-N bond
78
,  leads to NO release and 
thiyl radicals (GSH)
79
.  It is also important to mention that the formation of S-
nitrosothiols from endogenous NO intermediates readily reacts with glutathione to form 
naturally occurring GSNO
80,81
.  Singh et al. showed that NO cleavage from GSNO 
readily occurs in the presence of light as well as transition metal ions.  This group also 
claims that there is a transfer of NO
+
 from an S-nitrosothiol to a thiol
79
, this occurs 
through the presence of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH 
oxidizing substrate) and thioredoxin reductases in vivo
82
.  It could be postulated that the 
combination of metal ion chelators, specifically Cu
2+
 found in human smooth muscle cell 
cultures, along with additional cleavage occurring within the cell cytoplasm through the 
NADPH oxidizing substrate provides the necessary mechanism behind NO cleavage from 
GSNO molecules.  For instance Singh et al. showed that GSNO released roughly 3/4
ths
 of 
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its NO within 30 minutes and over 600 µM of NO from 1 mM GSNO in the presence of 
Cu
2+79
.     
 
Figure 1.3 Chemical structure of S-Nitrosoglutathione
83
 
Within physiological systems NO has many different functions in redox signaling
84–
87
.  Specifically, NO targets thiols that are specifically S-nitrosylated.  The nitrosylation 
of a Cys-residue in p21
ras
 activates the G protein, which plays a critical role in converting 
extracellular signals into intracellular biochemical events.   Finally, the oxidation of NO 
in vivo has been proven to be very slow and insignificant process making it a relatively 
stable structure in the absence of glutathione which creates endogenous GSNO
88
.   
1.7. Organization of thesis 
Data obtained in this thesis was organized into two separate experiments with the 
goal to describe the effects of delivering nitric oxide cues on HA-SMC proliferation, 
synthesis and deposition of vascular ECM (elastin, glycosaminoglycans, hyaluronic acid), 
release of inflammatory markers (MMPs-2, 9) and their inhibitors (TIMP-1), as well as 
matrix crosslinking enzymes (LOX).  The first of these experiments utilized cocultures of 
HA-SMC and HA-EC.  This was accomplished in both in a 3D microfluidic platform as 
well as 3D culture wells.  The innovative microfluidic design allowed for paracrine 
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signaling as well as more physiologically relevant imaging while the culture wells 
allowed for quantitative analysis of the effects of both NO cues as well as HA-ECs on 
HA-SMCs.  The second experiment was designed to utilize the key data obtained in the 
first and applied to diseased HA-SMCs with the exception of coculturing platform.  
Unlike the first experiment, culture wells were utilized in both 2D and 3D in order to 
properly translate data obtained in this thesis to future clinical relevance.  This thesis was 
designed to obtain a thorough understanding of the exogenously delivered NO on both 
healthy as well as diseased HA-SMCs to be relevant for drug and toxicology screening, 
tissue engineering and regenerative medicine therapies, as well as vascular disease 
remodeling.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
2.1. Microfluidic platform fabrication 
Coculturing vascular cells within 3D scaffolds, in close proximity to enable paracrine 
signaling, is difficult to accomplish using conventional cell culture techniques. This 
might partially explain the paucity of literature on this subject. Recent developments in 
microfluidic platforms might help overcome these limitations. The microfluidic device 
utilized in this study was created using photolithography and soft-lithography techniques 
as we detailed earlier
89
. Briefly, the device was designed in SolidWorks (SolidWorks 
Corp., Waltham, MA) and the mold developed at Stanford Microfluidics Foundry. Using 
this mold, microfluidic devices (Fig. 2.1) were created by replica molding with 
polydimethylsiloxane (PDMS: Dow Corning). PDMS was mixed with curing agent (10:1 
ratio), degassed and cured, removed from the mold and cut into separate devices. The 
devices were then sterilized in boiling water (45 min), and dried (80 °C, 2 h). The glass 
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cover slips were cleaned with ethanol and air plasma treated along with PDMS devices 
for 1 min before bonding, and devices stored till usage in a sterile environment. 
 
Figure 2.1 (A) Design of the microfluidic device for enabling biomimetic cocultures. (B) 
Cells could be cultured either alone or in the presence of other cell types within 
designated chambers of the device. These cell chambers have individual gel-filling ports, 
separated by microfluidic pillar posts, and could be supplemented with media through 
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separate channels. (C-E) HA-SMCs were cultured within collagen scaffolds, in the 
presence or absence of EC coculture and exogenous GSNO (0-100 nM dosage). 
 
2.2. Cell culture 
Healthy adult human aortic smooth muscle cells (HA-SMCs) and human aortic 
endothelial cells (HA-ECs) were obtained from Life Technologies Corp. (Carlsbad, CA) 
and passaged using appropriate media (Medium 231 and Medium 200, respectively; Life 
Technologies) provided.  Diseased adult human aortic smooth muscle cells (HA-SMCs) 
were isolated from abdominal aortic aneurysm segment of a 54-year old male, and 
provided at passage 2 by collaborators at INSERM U698, Paris, France. These cells were 
passaged in our lab using appropriated media (Medium 231; Life Technologies).  For 
experiments in this study, we used cells from passages 3-5 for healthy cells and 2-3 for 
diseased cells. Collagen gel (2 mg/ml; pH ~ 7.4) was prepared by mixing collagen stock 
solution (type-1, rat-tail derived, BD Biosciences, Bedford, MA) with a mixture of 10 
PBS, 1 M NaOH and DI water.  
 
2.2.1 Healthy cell cultures 
Two sets of cultures were performed in parallel: (i) HA-SMCs cultured alone, and (ii) 
HA-SMCs co-cultured with HA-ECs both in a well as well as a microfluidic platform. 
Results from the former set serves to (a) establish baseline data for adult human aortic 
SMC 3D cultures, (b) act as a control for the adult vascular 3D coculture data, and (c) 
rapidly scale up this process for further in vitro or in vivo studies. SMCs or ECs were 
mixed in 2 mg/ml collagen at a density of 10,000 cells per chamber. The device has two 
separate but adjacent 3D chambers (Fig. 2.1), each with individual gel-loading ports and 
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media channels. As shown in Fig. 2.1, in devices where SMCs were cultured alone, 
collagen gel containing SMCs were injected in the right chamber of the device, and 
collagen gel containing no cells in the left chamber. Similarly, in cases where cocultures 
were performed (Fig. 2.1), collagen gel containing ECs were injected in the left chamber, 
and gel containing SMCs in the right chamber. In this fashion, each cell type received its 
own media and GSNO dosage, but still in constant diffusive contact with neighboring cell 
type. Gels were injected into the respective gel-loading chambers with a cold-pipette tip 
containing ~7 µl of collagen solution. The devices were placed in a humidified incubator 
(37 °C, 30 min) to polymerize the collagen. Upon polymerization, cells were cultured for 
21 days in either SMC or EC media, containing S-Nitrosoglutathione (GSNO; Sigma, 
Saint-Louis, MO), an NO donor.  
As detailed in Fig. 2.1 (cases 1 and 2), four different concentrations of GSNO (0, 1, 
10, 100 nM) were tested for their ability to induce changes in SMC proliferation and 
matrix synthesis. GSNO concentration at 0 nM acts as a control for higher GSNO 
concentrations in each case. We choose not to coculture HA-SMCs with HA-SMCs (in 
separate chambers), due to minimum benefits from autocrine signaling. These devices 
could be scaled up in dimensions, for culturing larger gel volumes or higher cell 
densities.  As for the well culture platform 300 µl of collagen gel containing 10,000 cells 
was seeded into a 48-well plate.  Plates were placed in the humidified incubator (37 °C, 
30 min) to polymerize the collagen and then cultured for 21 days in a similar method to 
the microfluidic device.  The main difference was that in the case of coculture the HA-EC 
spent media was transferred to the HA-SMC cultures.  Media was changed once a day 
and the spent medium was pooled over the 21 day culture and stored at -20 °C for further 
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biochemical analyses. Similarly, cell matrix layers at the end of 21 days were trypsinized 
(one chamber at a time) and pooled from respective chambers and processed for 
biochemical assays as detailed below. 
 
2.2.1 Diseased cell culture 
Two sets of cultures were performed in parallel: (i) Aneurysmal HA-SMCs cultured 
on 2D substrates, and (ii) HA-SMCs cultured within 3D collagen hydrogels. To seed the 
wells in 3D cultures, SMCs were mixed in 2 mg/ml collagen at a density of 10,000 cells 
per well, while in 2D seeding the 24-well plates were first coated with a layer of 50 
µg/ml collagen and then 10,000 cell were placed in each well.  The cultures were placed 
in a humidified incubator (37 °C, 30 min) to polymerize the collagen.  Upon 
polymerization, cells were cultured for 21 days in SMC media, containing S-
Nitrosoglutathione (GSNO; Sigma, Saint-Louis, MO), an NO donor.  Two different 
concentrations of GSNO (0 and 100 nM) were tested for their ability to induce changes in 
SMC proliferation and matrix synthesis, based on outcomes identified in healthy cell 
cultures.  A total of 12 wells were seeded for both 2D and 3D cultures per concentration 
of GSNO.  GSNO concentration at 0 nM acts as a control for higher GSNO 
concentrations in each case.  Media was changed once a day and the spent medium was 
pooled into a single volume per case over the 21 day culture and stored at -20 °C for 
further biochemical analyses.  Similarly, cell matrix layers at the end of 21 days were 
trypsinized (one chamber at a time) and pooled from respective chambers and processed 
for biochemical assays as detailed below.  
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2.3. Biochemical analyses 
The characterization of the ECM synthesized by both the healthy and diseased HA-
SMCs was performed by the assays as described in the sections below.  For each of these 
assays there were conducted on both the cell matrix as well as the pooled media (1 case 
per assay with n=3 per case unless otherwise noted) following the 21 day culturing 
period.  For healthy cell cultures, cells were seeded within one well per assay due to 
extremely low proliferation rate of adult HA-SMCs, low survival after passaging, and the 
prohibitive costs in obtaining large cell densities required for seeding in larger number of 
wells .  To prepare each sample for their respective assay the cell matrices were detached 
by incubating them with Trypsin 1 for 8-10 min.  Once the cells were detached from 
each well the suspensions were centrifuged at 2800-3000 rpm for 10-12 min.  Following 
the centrifugation, the supernatant was discarded leaving the pellet in the microcentrifuge 
tube.  The pellet were resuspended in 300 µL of 1x PBS.  Similarly the pooled media that 
was collected from each well and stored at -20 °C, was thawed and distributed in 1 mL 
increments to labeled microcentrifuge tubes and centrifuged at 12000 rpm for 15 min.  
Once the centrifuging was complete the supernatant was discarded and the pellet was 
resuspended in 300 µl of 1x PBS.  All samples were then stored in -20 °C until further 
use.  Before the start of any assay the samples were thawed at room temperature.       
 
2.3.1. DNA assay for cell proliferation  
The cell density within different cases was quantified at the end of both 1 and 21 days 
to assess the proliferation of healthy or diseased HA-SMCs and HA-ECs over the culture 
period. Briefly, media was removed from the media channels, and 0.25% v/v trypsin-
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EDTA (Invitrogen) was added to the channels, cell layers were detached and extracted 
separately from each chamber, pelleted by centrifugation, resuspended in NaCl/Pi buffer, 
and assayed using a fluorometric assay, as we detailed earlier
89
. The cell density was 
calculated on the basis of an estimated 6 pg DNA/cell
90
. 
 
2.3.2. BCA assay for total protein synthesis 
The total amount of protein synthesized by HA-SMCs under various culture 
conditions was determined using bicinchoninic acid protein assay kit (BCA Kit, Sigma-
Aldrich), as per the vendor’s protocols.  Once thawed 25 µl of each sample were pipetted 
into a 96-well plate (Greiner Bio One, Monroe, NC) along with the standards that were 
prepared according to the venders protocol of 25 µg/ml, 125 µg/ml, 250 µg/ml, 500 
µg/ml, 750 µg/ml, 1000 µg/ml, 1500 µg/ml, and 2000 µg/ml.  To each of the wells 
containing either a sample or a standard 200 µl of BCA working solution was added and 
mixed on a mechanical shaker for 30 seconds.  This assay is based on the principle that a 
Cu
2+
-protein complex forms under alkaline conditions, followed by reduction of the Cu
2+
 
to Cu
1+
 based on the amount of protein present in the sample and has a working range of 
20-2000 µg/mL (all data obtained was within this range). The total protein in the pooled 
spent media as well as in the cell matrix at the end of 21 days was quantified (n = 6 
devices/condition). 
 
2.3.3. Fastin assay for elastin protein 
The amounts of matrix elastin and tropoelastin (in pooled spent medium) were 
quantified using a Fastin assay (Accurate Scientific Corp, Westbury, NY, USA).  Since 
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the Fastin assay quantifies only soluble α-elastin, the matrix elastin was first reduced to a 
soluble form and has a working range of 5-70 µg (all data was found within this range 
and n=4 for healthy monocultures and cocultures).  This was accomplished by digesting 
the samples with 1 M oxalic acid at 100 °C for one hour.  The samples were then 
transferred to a 2 ml microcentrifuge tube and with an equal amount of elastin 
precipitating reagent.  Along with this step the elastin precipitating reagent was also 
added to the blanks and standards (12.5 µl, 25 µl, and 50 µl).  It is important to note that 
both samples and standards were run in duplicate in accordance to the Fastin elastin assay 
protocol.  Once the elastin precipitating reagent was added to all samples and standards 
each tube was vortexed and left at room temperature for 15 minutes.  Following the 15 
minutes the tubes were centrifuged at 10,000 g for 10 minutes and following the 
supernatant was removed.  The pellet containing the elastin precipitate was suspended in 
1 ml dye reagent and homogeneously mixed on a mechanical mixer at room temperature 
for 90 minutes.  Following incubation, each tube was centrifuged as described above and 
250 µl Dye dissociation reagent was added to each tube once the supernatant was 
removed.  The pellet was then dispersed by vortexing twice with a 10 minute interval.  
The suspension was then transferred to a 96-well microplate and the absorbance was 
measured at 513 nm with a microplate spectrophotometer.  The measured amounts of 
matrix elastin and tropoelastin were normalized to their respective cell counts to provide 
a reliable basis of comparison between samples. 
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2.3.4. sGAG assay for glycosaminoglycan synthesis 
The amounts of sulfated glycosaminoglycans deposited within the cellular matrix as 
well as in the pooled spent medium were quantified using a quantitative dye-biding 
sGAG Assay (Kamiya Biomedical Company, Seattle, WA) as per vendor’s protocols.  A 
volume of 50 µl in duplicated of standards, blanks, controls, and samples were diluted 
with 50 µl of 8M Guanidine-HCL and incubated for 15 minutes at room temperature.  50 
µl of 0.3% (GuHCl) and incubated for 15 min at RT. A diluent composed of 0.3% 
H2SO4 and 0.75% Triton X-100 was added to each vial and mixed at room temperature 
for 15 minutes on a mechanical mixer.  Once mixed, 750 µl of Alcian blue working 
solution was added to each vial.  To allow the Alcian blue to bind to the sGAG the vials 
were incubated overnight at 4°C.  The following day the vials were centrifuged at 12000 
for 15 minutes.  The supernatant was then removed and the pellet was resuspended in 500 
µl DMSO solution and mixed for 15 minutes at room temperature.  Following the 
mixing, the vials were then centrifuged again as previously with the supernatant being 
discarded and 500 µl of Gu-Prop (4M GuHCl + 33% 1-propanol + 0.25% Triton X-100) 
was added.  Once the pellet was dissolved the samples were loaded onto a 96-well plate 
and the absorbance values were read at 620 nm on an Epoch
TM
 microplate 
spectrophotometer (Bio-Tek, Winooski, VT), and the measured sGAG amounts were 
normalized to the corresponding cell counts (n = 6 devices/condition for the healthy 
monoculture and cocultures).  This assay is based on the specific interactions between 
sulfated GAGs and the tetravalent cationic dye Alcian blue, at low pH and optimized 
ionic strength and has a working range of 12.5-400 µg/mL.  Most data points were not 
within this range increasing the amount of error.  To obtain results a smaller standard 
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curve was calculated using the low standards which allowed for the calculation of GAG 
molecules in the lower ranges. It should be noted that this assay will not quantify the non-
sulfated GAGs such as hyaluronic acid.  
 
2.3.5. HA assay for hyaluronic acid synthesis 
Hyaluronic acid synthesized and released by SMCs within the cellular matrix as well 
as in the pooled spent medium was quantified using a hyaluronan enzyme-linked 
immunosorbent quantitative assay (Echelon Biosciences Inc., Salt Lake City, UT).  HA 
concentration in the sample is determined using a standard curve of known HA amounts.  
This assay works best with HA molecules that are greater than 25 repeating units.  
Because this assay has a working limit depending on the number of repeating units it is 
difficult in the scope of this study to ensure the presence of any HA molecules that are 
shorter than 25 repeating units.  A volume of 100 µl samples and standards were pipetted 
in the provided 96-well incubation plate.  To act as the zero HA control in this assay 100 
µl of 1x HA diluent was utilized while for the blank control 150 µl of the diluent was 
used.  50 µl of the diluted HA working detector was added to each of the wells except for 
the ones filled with the blank controls.  Following the addition of the diluted HA working 
detector the plate was gently mixed and incubated for one hour at 37 °C.  Once the 
incubation period was complete 100 µl of the solution was transferred from each well to 
the corresponding well in the pre-coated HA detection plate.  The detection plate was 
then incubated for 30 minutes at 4 °C and then each well was washed four times with 1x 
wash concentrate making sure to invert and remove all wash concentrate onto an 
absorbent paper towel.  After the washing step was complete 100 µl of working enzyme 
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was added to each well and incubated for 30 minutes at 37 °c.  The washing procedure 
described above was repeated following the incubation and 100 µl of working substrate 
solution was added to each well.  The detection plate was then incubated in the absence 
of light at room temperature for 15 minutes and the absorbance was measured.  
Absorbance values were read at 450 nm on an Epoch
TM
 spectrophotometer every 15 
minutes until the ratio between the zero HA control and the 1600 ng/ml HA standard is 
higher than 3.  This ratio indicates the completion of the reaction and to add the stop 
solution to each well.  The measured HA content was normalized to the corresponding 
cell counts (n = 6 devices/condition). 
 
2.3.6. LOX functional activity 
Studies have shown that lysyl oxidase (LOX) and LOX-like proteins are endogenous 
enzymes responsible for crosslinking elastin precursor (tropoelastin) molecules. Thus, 
estimating the endogenous LOX activity in the cellular matrix as well as in pooled 
medium indicates the extent of cell-mediated crosslinking of tropoelastin to form mature 
elastin matrix structures. Using a fluorometric assay (AmplexRed® Assay; Molecular 
Probes, Eugene, OR), we assayed for LOX activity within the cell matrix and pooled 
spent culture medium aliquots from different culture conditions. This assay works on the 
principle that H2O2 will be released when LOX oxidatively deaminates alkyl 
monoamines and diamines and has been used to detect as little as 10 pM of H2O2 in a 
100µL volume (all measured values are above this detection limit).  Firstly, the standards 
were prepared (0, 2, 4, 6, 8, and 10 µM) and 50 µl of each standard and samples were 
pipetted into a 96-well microplate with 50 µ of working solution (100µM Amplex Red 
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reagent, 1:2, 0.2 U/ml Horseradish peroxidase).  The microplate was then incubated in 
the dark for 30 minutes at room temperature.  Fluorescence intensities were recorded with 
excitation and emission wavelengths of 560 and 590 nm, respectively (560 nm gave the 
best standard curve and thus was used). The measured activity was normalized to the cell 
density within that respective culture condition (n = 3 devices/condition). 
 
2.3.7. Quantification of MMPs-2, 9 and TIMP-1 release 
The amounts of MMPs-2 and 9 deposited within the cellular matrix as well as in the 
pooled spent medium were quantified using MMP-2 ELISA (Boster Biological 
Technology Co., Fremont, CA) and MMP-9 ELISA (R&D Systems, Inc., Minneapolis, 
MN) assays as per vendor’s recommendations. The amount of TIMP-1 deposited within 
the cellular matrix as well as in the pooled medium was quantified using a TIMP-1 
ELISA (Boster Biological Technology Co.). The measured MMPs and TIMP-1 content 
was normalized to the respective cell count within those cultures (n = 6 
devices/condition).  For the MMP-2 ELISA the sensitivity is < 10 pg/mL, MMP-9 ELISA 
is <13 pg/mL, and TIMP-1 ELISA is < 3 pg/mL.  Samples studied from the cell matrix 
showed insignificant amounts of MMPs and TIMPs making it hard to accurately quantify 
the actual amount of each protein however samples obtained from the pooled media all 
showed values larger than the working limit. 
 
2.3.7.1 Quantification of MMPs-2 and TIMP-1 
The same provided protocol procedure was followed for both the MMPs-2 and TIMP-
1 assays.  Firstly, each sample was diluted 2:1 with the provided diluent buffer and then 
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100 µl of each sample was pipetted in the corresponding MMP-2 and TIMP-1 specific 
antibody pre-coated 96-well plate.  Following, 100 µl of the respective standards were 
then pipetted into the respective plates.  The microplates were then covered and incubated 
at 37 °C for 90 minutes.  Ensuing the incubation, each plate was carefully blotted on an 
absorbent paper allowing the wells to dry and then the plates were incubated for one hour 
at 37 °C with 100 µl biotinylated anti-rat MMP-2 and TIMP-1 antibody working 
solutions added to their respective wells.  Next, the solution was discarded from each 
microplate and each well was then washed three times with 1x PBS.  Following the 
washing step, the plates were incubated with 100µl of 1x Avidin-Biotin-Peroxidase 
Complex for 30 minutes at room temperature.  The solution was then discarded and the 
wells were washed five times with 1x PBS.  90 µl TBM color developing agent was then 
added to each well and the plates were incubated at 37 °C for 30 minutes before the 
reaction was terminated with 100 µl of TMB stop solution in each well. The absorbance 
was read at 450 nm.       
  
2.3.7.2 Quantification of MMPs-9 
The MMP-9 ELISA assay is based on the quantitative enzyme-linked immunoassay 
method where the MMP-9 binds to a specific monoclonal antibody and a specific 
enzyme-linked polyclonal antibody.  50 µl of diluent RD1-34 was pipetted to each well in 
the provided pre –coated 96-well plate with 50 µl of standards and samples.  Once these 
two were added the plate was then covered and incubated for two hours at room 
temperature.  Following the incubation, the wells were washed with wash buffer five 
times and 100 µl of MMP-9 conjugate was added to each well.  The incubation and 
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washing step were repeated and then 100µl of substrate solution was added to each well.  
Following the addition of the substrate solution the plate was incubated in dark at room 
temperature for 30 minutes.  Lastly, 100 µl of stop solution was added to each well and 
the absorbance was measured at 450 nm and 570 nm.  To obtain the standard curve and 
thus the MMP-9 content the absorbance read at 570 nm was subtracted from 450 nm.   
 
2.4. Immunofluorescence imaging of matrix proteins 
The presence of elastin, fibrillin and LOX proteins within cell matrix were 
qualitatively confirmed using immunofluorescence labeling (n = 3 devices/condition for 
each protein). The presence of fibrillin within cell layers will confirm whether elastin 
matrix formation was mediated by pre-deposition of a fibrillin scaffold. At 21 days, the 
cell layers within microfluidic devices were fixed with 4% w/v paraformaldehyde for 15 
min, and incubated with blocking serum (5% goat serum, 0.3% Triton-100 in phosphate-
buffered saline; 20 min; 25 °C). Elastin, fibrillin and LOX were detected with respective 
polyclonal antibodies (1% antibody in 1X PBS, 5% goat serum, 0.1% Trition-X, Elastin 
Products; Abcam; Santa Cruz Biotechnology), which were incubated overnight at 4 °C on 
a mechanical shaker.  Once incubation was complete each cell culture was washed 3 
times with 1x PBS, allowing 5 minute intervals between washes and then appropriate 
secondary antibodies (0.4% antibody in 1x PBS, 5% goat serum, 0.1% Triton-X, 
Chemicon, Temecula, CA) were added and incubated at room temperature in the dark for 
20 minutes.  Cell nuclei were visualized with the nuclear stain 4’, 6- diamino-2-
phenylindole dihydrochloride (DAPI) contained in the mounting medium (Vectashield; 
Vector Labs, Burlingame, CA) and 1X PBS was added to preserve cell culture till 
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florescence imaging was performed. Images were acquired with a Zeiss Axiovert A1 
florescence microscope equipped with Hamamatsu camera and image acquisition 
software.  Please see Table 2.1 for proper antibodies to be used in Immunofluorescence 
imaging. 
Table 2.1 Summary of antibodies used in immunofluorescence analysis. 
Primary Antibody Host Clonality Concentration (v/v) 
Elastin Rabbit Polyclonal 1;100 
LOX Rabbit Polyclonal 1;100 
Fibrillin Rabbit Polyclonal 1;100 
Secondary 
Antibody 
Host Clonality Concentration (v/v) 
Goat anti-Rabbit Goat Poluclonal 1;250 
 
2.5. Cellular Dimensions 
 The dimensions of the healthy and diseased phenotype were imaged using a Zeiss 
Axiovert A1 florescence microscope equipped with Hamamatsu camera and image 
acquisition software.  Six cases per cell type were used and processed through ImageJ 
software where each perimeter and area was calculated.  Each case was sampled during 
the 3-5 passages and seeded on a T-25 plate with Medium 231. 
 
2.6. Statistical analysis 
All biochemical data were obtained from three independent repeat experiments per 
case, and were analyzed using Student’s t-test and one-way ANOVA, assuming unequal 
variance and differences deemed significant for p < 0.05. The data were assumed to 
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follow a near-Gaussian distribution in all the cases, and the mean and standard errors 
were calculated accordingly. 
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CHAPTER III 
 
RESULTS AND DISCUSSION: HEALTHY HUMAN SMCS WITHIN 
COCULTURES 
  
3.1. HA-EC and HA-SMC proliferation 
The proliferation of HA-ECs and HA-SMCs cultured in the presence or absence of 
GSNO are shown in Fig. 3.1. In the absence of GSNO (controls), ECs proliferated ~ 3-
fold over 21 days, compared to their original seeding density (Fig. 3.1 A). The addition 
of 1 or 10 nM GSNO promoted EC proliferation by ~4.1-fold and 4.8-fold respectively, 
compared to day 1 seeding (p < 0.01 vs. controls in both the cases). Addition of 100 nM 
GSNO offered no further benefit to EC proliferation compared to controls (p = 0.2 vs. 
controls). In the presence or absence of GSNO, trends in SMC proliferation rates were 
different from that of ECs. When SMCs were cultured alone in the absence of ECs, 
increasing GSNO concentration suppressed SMC proliferation within 3D collagen 
scaffolds over the 21 day period (Fig. 3.1 B). SMCs proliferated ~ 3.2-fold in the absence 
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of GSNO, and that reduced to 2.9-fold, 2.4-fold and 2-fold respectively, in the presence 
of 1, 10 and 100 nM GSNO (p < 0.01 for 0 nM vs. 10 nM or 100 nM; p < 0.01 for 1 nM 
vs. 100 nM). In the presence of EC cocultures, SMCs proliferated almost 4.8-fold and 
3.9-fold respectively, at 0 nM and 1 nM GSNO concentrations (p < 0.01 for EC coculture 
vs. no coculture, under respective conditions; p < 0.01 for 0 nM vs. 1 nM GSNO). 
However, SMC proliferation rates significantly decreased to 2-fold and 1.4-fold, with the 
addition of 10 nM and 100 nM GSNO respectively, within cocultures (p < 0.01 for 10 
nM vs. lower concentrations of GSNO; p < 0.01 for 100 nM vs. lower concentrations of 
GSNO; p < 0.01 for 10 nM vs. 100 nM GSNO). 
Previous studies have shown that the half-life of GSNO ranges from 5.5 h to 24 h, 
depending on pH and environmental conditions
82,91
, and is considerably higher than that 
of pure NO (typically a few minutes)
92
. Therefore, we choose to replace the culture 
medium twice a day, so that fresh NO is delivered to the cells within cultures. Besides, 
the NO release from GSNO concentrations tested here are within the physiological 
levels
92
, which makes this study a good starting point for further in vivo optimization 
studies. Given that NO is an unstable gas and endogenous NO levels are impossible to 
quantify or manipulate, exogenous aerosolized NO delivery has been used to positively 
modulate circulating levels of NO within cystic fibrosis patients
93
. In this study, we did 
not investigate the NO activity and release rates from GSNO within culture media at 
neutral pH, as it has been extensively reported earlier
94,95
. Given the low molecular 
weight, it takes less than 20 min for GSNO (or NO) to diffuse across the 3D collagen 
scaffold within the microfluidic device and saturate the entire cell culture region. 
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Exogenously delivered NO has been shown to suppress proliferation of endothelial 
cells derived from fetal bovine aorta and human umbilical veins in a dose-dependent 
manner
96
, via an intracellular cGMP mechanism. In contrast, we noticed here that lower 
GSNO dosage (1-10 nM) promoted modest HA-EC proliferation, while the stimulatory 
effect was attenuated at 100 nM GSNO. Our results on the dose-dependent inhibitory 
effects of GSNO on HA-SMC proliferation are in excellent agreement with similar 
studies evaluating the role of NO donors (e.g., DEA NONOate, sodium nitroprusside, 
nitroglycerin, SNAP) on human, rabbit, chick or rodent SMCs, both in vitro and in 
vivo
74,92,94,97
. It is worth mentioning that cell toxicity was not noted within our cultures 
(from LIVE/DEAD assay analysis; data not shown) in the presence of GSNO, and the 
cell morphology appeared identical in both controls and test cases. SMC proliferation 
data within cocultures was also in agreement with studies by Fillinger et al., who reported 
that within bovine aortic cell 2D cocultures, ECs stimulated SMC proliferation by ~56% 
compared to culturing SMCs alone
98
. Taken together, our results unequivocally suggest 
that vascular cell proliferation is differentially modulated by exogenous NO delivery, 
with significant implications in vascular remodeling under healthy and diseased 
conditions. 
Figure 3.1 (A) Fold increase in HA-EC density within 3D cultures supplemented with 
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GSNO (0-100 nM). (B) Proliferation ratios of HA-SMCs in the presence or absence of 
EC cocultures and GSNO (0-100 nM). Data shown represent mean ± standard error of 
cell count after 21 days of culture, normalized to initial seeding density (n = 3/ 
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 
no cocultures vs. EC coculture, at a given GSNO dosage. 
 
 
3.2. Total protein synthesis by HA-SMCs 
The total protein amounts synthesized by HA-SMCs, in the presence or absence of 
ECs, were quantified as two separate components: released into pooled spent media and 
that deposited in cell matrix. HA-SMCs produced and deposited ~131 ± 19 ng of protein 
within cell matrices, on a per cell basis, when cultured alone in the absence of GSNO 
(Fig. 3.2 A). Although 1 and 100 nM GSNO offered no further benefits to protein 
deposition within these SMC cultures, 10 nM GSNO significantly suppressed protein 
deposition within SMC cultures (~ 67.8 ± 9 ng of protein; p < 0.001 for 10 nM vs. all the 
other cases). On the other hand, coculturing SMCs with ECs did not improve protein 
deposition in cell matrix in the absence of GSNO. Within EC cocultures, only 100 nM 
GSNO stimulated a 2.2-fold increase in total protein deposition within cell layers, 
compared to GSNO-free cultures (p < 0.001 for 100 nM vs. lower GSNO doses). 
HA-SMCs released ~ 2 ± 0.15 µg of protein into pooled media on a per cell basis, 
over the 21 day culture, in the absence of EC cultures and GSNO (Fig. 3.2 B). While the 
addition of 1 nM and 10 nM GSNO did not alter these amounts, 100 nM GSNO 
upregulated protein release by 1.54-fold compared to non-additive controls (p = 0.008). 
Surprisingly, coculturing with ECs significantly suppressed protein release into pooled 
media by SMCs, on a per cell basis, compared to their stand-alone cultures (Fig. 3.2 B; p 
< 0.001 for no coculture vs. EC coculture controls). Addition of 1 nM GSNO did not 
rescue this decrease in protein synthesis and release by SMCs within cocultures. 
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However, 10 nM and 100 nM GSNO addition stimulated 1.42- and 3.66- fold increases in 
protein synthesis by SMCs within EC cocultures, compared to controls (p = 0.026 and p 
< 0.001, respectively, compared to controls). Taken together, results suggest that 100 nM 
GSNO dosage significantly increased total protein synthesis, release into pooled media 
and deposition within cell matrix layers, in the presence or absence of EC cocultures. 
The effects of NO on matrix protein synthesis by SMCs or any other mammalian cell 
types has been reported in a very few studies thus far. Kolpakov et al. have shown that 
NO donors such as SNAP (0.4-1.2 mM) and SNP (0.1-0.5 mM) inhibited total protein 
synthesis and collagen synthesis by rabbit aortic SMCs in vitro in a reversible but dose-
dependent manner
99
, highlighting the strong role of NO in modulating SMC phenotype. 
In another study, SNAP inhibited total protein synthesis by rat aortic SMCs in a time-
dependent manner, when cultured in the presence of 5% fetal calf serum
100
. Curran et al. 
have shown that SNAP inhibited total protein synthesis by hepatocytes in a reversible but 
dose-dependent manner
101
. These results are in agreement with our observations, where 
NO delivered via GSNO did not significantly enhance total protein synthesis by HA-
SMCs, except at 100 nM dosage and EC coculture. Although the molecular mechanisms 
behind this NO-mediated inhibition of protein synthesis by SMCs remains categorically 
unexplored and beyond the scope of this work, previous studies suggest that multiple 
biochemical pathways might be involved in mediating this process
99
. 
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Figure 3.2 Total protein amounts deposited within cell matrix (A) or released into pooled 
media (B), when GSNO (0-100 nM) was supplemented to HA-SMC cultures, in the 
presence or absence of HA-EC cocultures. Data shown represent mean ± standard error 
of protein synthesis after 21 days of culture, normalized to cell count within respective 
cases (n = 6/ condition). * indicates p < 0.05 compared to GSNO-free cultures; # 
indicates p < 0.01 for no cocultures vs. EC coculture, at a given GSNO dosage. 
 
 
3.3. Elastin synthesis and deposition by HA-SMCs 
The total elastin synthesized by HA-SMCs was quantified as that released into pooled 
media (i.e., tropoelastin) and that deposited into the cell layers (i.e., matrix elastin). In the 
absence of EC coculture and GSNO, HA-SMCs released 7.05 ± 1.1 ng of tropoelastin on 
a per cell basis over the 21 day culture (Fig. 3.3 A). Within SMC cultures, the 
tropoelastin content increased to 11.8 ± 2.2, 42.3 ± 5.4 and 29.9 ± 4.7 ng respectively, in 
the addition of 1, 10 and 100 nM GSNO (p < 0.01 for 0 nM vs. higher GSNO dosages). 
Thus, in the absence of EC cocultures, 10 nM GSNO appeared to stimulate higher 
tropoelastin synthesis and release by HA-SMCs (p < 0.01 vs. all other GSNO dosages). 
Even in the absence of GSNO, coculturing with ECs stimulated significantly higher 
amounts of tropoelastin release by SMCs (Fig. 3.3 A; 20.6 ± 3.8 ng per cell) compared to 
that within no coculture cases (p < 0.001 for EC coculture vs. no coculture). Within 
cocultures, addition of 10 nM or 100 nM GSNO furthered tropoelastin synthesis by 2.4- 
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and 3.2- fold respectively, compared to that seen in controls (p < 0.001 for 0 nM vs. 10 
nM or 100 nM GSNO). However, no significant benefit of cocultures to tropoelastin 
synthesis was noted at 1 nM GSNO dosage. 
In the absence of EC cocultures, matrix elastin deposited within HA-SMC cultures 
was undetectable at 0 nM GSNO (Fig. 3.3 B). However, with increasing GSNO dosage, 
matrix elastin amounts on a per cell basis increased in a linear fashion, with significant 
differences noted between incremental GSNO dosages (p < 0.01 for 0 nM vs. 1 nM, 1 nM 
vs. 10 nM, and 10 nM vs. 100 nM). Even in the absence of GSNO, coculturing with ECs 
resulted in the deposition of 1.76 ± 0.25 ng of matrix elastin by SMCs, on a per cell basis. 
Within EC cocultures, addition of 1, 10 and 100 nM GSNO resulted in 1.2-, 2.9- and 4-
fold increases in matrix elastin synthesis on a per cell basis, compared to GSNO-free 
controls (p < 0.01 for 10 nM vs. 0 nM, and for 100 nM vs. 0 nM). Taken together, results 
suggest that (a) although adult HA-SMCs produce quantifiable tropoelastin over the 21 
day culture period, they do not deposit detectable amounts of matrix elastin, in the 
absence of GSNO; (b) coculturing with ECs significantly upregulated tropoelastin and 
matrix elastin by adult HA-SMCs, even in the absence of GSNO; (c) GSNO addition 
significantly enhanced both tropoelastin release and matrix elastin deposition by SMCs in 
a dose-dependent manner, in the presence or absence of EC cocultures; and (d) EC 
coculture and 100 nM GSNO synergistically contributed to multi-fold increases in tropo- 
and matrix elastin by adult HA-SMCs. 
From the data shown in Figs. 3.3 A and B, the matrix elastin yield (ratio of matrix 
elastin to the total elastin produced) within these HA-SMC cultures was calculated. When 
SMCs were cultured alone in the absence of ECs, the matrix elastin yields were 5%, 2.3% 
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and 4.1% within 1 nM, 10 nM and 100 nM GSNO additive-cultures, respectively. 
However, EC cocultures significantly enhanced matrix elastin yields, both in the presence 
or absence of GSNO. The matrix elastin yield within 0 nM, 10 nM and 100 nM GSNO 
additive cultures were 7.8%, 9.3% and 9.8%, respectively (p < 0.001 for no coculture vs. 
EC coculture, at respective GSNO doses). Surprisingly, addition of 1 nM GSNO resulted 
in ~ 40% matrix elastin yield, significantly higher than that noticed in all the other 
coculture cases. 
Despite recent progress in the field of vascular tissue engineering, elastin synthesis 
and deposition by vascular SMCs within 3D constructs remain a formidable 
challenge
102,103
. This is partially due to highly reduced ability of adult SMCs (at both 
transcription and translation levels) to synthesize, release, and deposit mature elastin. 
Thus, the overarching goal of cellular or tissue engineering approaches is to stimulate 
these adult SMCs, using an optimal combination of biochemical and biomechanical cues, 
to deposit mature and cross-linked elastin within blood vessels. In a series of studies, we 
have shown that exogenous cues such as hyaluronan oligomers, TGF-ß1, IGF-1 and LOX 
induced increases in elastin synthesis within 2D cultures of adult rat aortic SMCs
89,104–107
. 
In a series of recent studies, Lin et al. have shown that surface topography strongly 
affects elastin gene expression and protein synthesis by adult human coronary artery 
SMCs
108,109
. Elastin gene expression and protein synthesis by these cells increased 
significantly when cultured within 3D porous polyurethane scaffolds compared to their 
2D culture counterparts, and the addition of TGF-ß1 to these cultures furthered these 
trends. Such increases in elastin expression by SMCs within these 3D scaffolds were 
facilitated by Ras-ERK1/2 signal transduction pathways. However, these cells were 
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cultured only up to 14 days, which is not sufficient for elastin matrix deposition and 
maturation within cell layers. Ramamurthi and coworkers recently showed that adult 
human and rat SMCs produced higher elastin protein within 3D collagen gels exposed to 
exogenous growth factors or cyclical stretching conditions
110,111
. These studies point to 
the overall superiority of 3D scaffolds over 2D cultures, in stimulating elastin synthesis 
and release by SMCs. 
Thus, in this study, we cultured HA-SMCs within 3D collagen scaffolds to mimic 
physiological conditions, and enable future tissue engineering based approaches for in 
situ elastin regeneration. We noted multi-fold increases in tropoelastin production and 
matrix elastin deposition within HA-SMC 3D cultures, in the presence of GSNO and EC 
cocultures. A study by Sugitani et al. was the only known report which evaluated the role 
of NO on elastin expression and synthesis by chick aortic SMCs
74
. Although elastin 
deposition into matrix was not evaluated by them, results showed NO to stimulate 
tropoelastin mRNA expression, synthesis and release into pooled media by chick cells in 
a dose-dependent manner (1-100 nM), with the maximum stimulation noted at 100 nM 
GSNO. In our current study, the excellent elastin matrix yield of ~40% noticed within 1 
nM GSNO and EC cocultures was not only relevant to vascular biology studies, but also 
highly encouraging from tissue engineering and regenerative medicine based stand-
points. However, further studies are needed to quantify the changes in elastin gene 
expressions under these culture conditions.  
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3.4. Glycosaminoglycan synthesis by HA-SMCs 
Studies have shown that chondroitin sulfate and heparan sulfate were the main 
constituents of sGAGs produced by human aortic SMCs
112
. Suarez et al. have shown that 
growth factors such as EGF, FGF and VEGF stimulate SMCs to synthesize heparin 
sulfate in a dose-dependent manner
113
. However, the role of NO or EC cocultures in 
mediating GAG (sulfated or non-sulfated) synthesis remains unexplored, and this study 
reports for the first time the dose-dependent effects of NO donors on GAG synthesis by 
human aortic SMCs. In general, the GAG content within the cell layers and pooled media 
was quantified as sulfated GAGs (sGAGs) and non-sulfated GAGs (HA). In the absence 
of EC cocultures, adult HA-SMCs released 16.7 ± 3.2 ng of sGAGs into pooled media on 
a per cell basis, within GSNO-free cultures (Fig. 3.3 C). GSNO addition (1-100 nM) 
significantly suppressed sGAG release into pooled media when compared to controls (p < 
0.001). On the other hand, no further benefit of EC coculture to sGAG release into pooled 
media was noticed within GSNO-free cultures. Within EC cocultures, addition of 1 nM 
GSNO suppressed sGAG release by SMCs (p < 0.01 for 1 nM vs. 0 nM), while 10 and 
100 nM GSNO stimulated 1.4–fold and 1.95–fold increases in sGAG release 
respectively, compared to controls (p < 0.01 for 0 nM vs. 10 nM or 100 nM; p < 0.01 for 
1 nM vs. 10 nM or 100 nM; p < 0.01 for 10 nM vs. 100 nM GSNO). Taken together, 
except within GSNO-free cultures where significant differences were not noticed, 
coculturing with HA-ECs appeared to stimulate sGAG release by HA-SMCs in a GSNO 
dose-dependent manner. 
The sGAG content deposited within cell matrices seem to reflect the trends observed 
in matrix elastin synthesis by HA-SMCs. sGAGs presence could not be detected within 
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HA-SMC cell layers in the absence of EC coculture and GSNO (Fig. 3.3 D). However, in 
the absence of EC cocultures, increasing GSNO concentration from 1-100 nM promoted 
significant sGAGs deposition in the cell layers in a dose-dependent manner (p < 0.01 for 
1 nM vs. 10 nM or 100 nM; p < 0.01 for 10 nM vs. 100 nM). In the presence of EC 
cocultures, SMCs deposited 0.62 ± 0.19 ng of sGAGs in the cell layers, on a per cell 
basis, within GSNO-free cultures. While 1 and 10 nM GSNO did not further promote 
sGAG deposition into matrix layers within EC cocultures, addition of 100 nM promoted a 
drastic 7.4-fold increase in sGAG deposition within cell layers, relative to GSNO-free 
controls (p < 0.001 for 100 nM vs. lower GSNO doses). In general, the matrix sGAG 
yield (ratio of matrix sGAG content to the total sGAGs produced) within SMC cultures 
ranged between 0 - 10 %, while EC cocultures significantly promoted the same to 
between 4.2 - 14.5 %. Taken together, results show that 100 nM GSNO stimulated 
synthesis, release and deposition of sGAGs by HA-SMCs within a biomimetic vascular 
coculture environment. 
The release of non-sulfated GAGs within SMC cultures was different from sGAG 
trends. SMCs released ~ 2 ± 0.23 pg of HA into pooled media on a per cell basis, in the 
absence of GSNO and EC cocultures (Fig. 3.3 E). Although no further benefits to HA 
release were realized at lower GSNO dosages (1 and 10 nM), a 1.55-fold increase in HA 
content was noted at 100 nM GSNO relative to controls (p < 0.01 for 100 nM vs. lower 
doses of GSNO). However, in the presence of EC cocultures, GSNO at 0 nM and 1 nM 
suppressed HA release by SMCs into pooled media, although this suppression was 
rescued at higher GSNO dosages. HA release into pooled media was enhanced by 2.4-
fold and 3.2-fold, within cultures supplemented with 10 and 100 nM GSNO respectively, 
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within EC cocultures (p < 0.001 for both cases vs. 0 nM cultures). The trends in HA 
deposition within cell matrix (Fig. 3.3 F) mirrors that noted in sGAG deposition within 
respective cultures. When SMCs were cultured alone, 0.2 ± 0.03 pg of HA was deposited 
within cell layers on a per cell basis, and addition of GSNO at 1 and 10 nM dosages did 
not further enhance these deposition levels. However, in the presence of 100 nM GSNO, 
a 2.44-fold increase in HA deposition was seen (p < 0.001 for 100 nM vs. lower GSNO 
dosages), even in the absence of EC cocultures. Interestingly, no additional benefits of 
EC coculture to HA matrix deposition was noted at 0 nM or 1 nM GSNO dosages (Fig. 
3.3 F). A dramatic 2.56-fold and 21.9-fold increase in HA deposition within cell layers 
was noted when GSNO was supplemented at 10 nM and 100 nM respectively, to SMCs 
within EC cocultures. 
Quantification of HA matrix yield (ratio of HA within cell matrix to total HA 
synthesis) revealed that the yield increased from ~ 9% within 0-10 nM GSNO cultures to 
13.4% within 100 nM GSNO-additive cultures, in the absence of EC cocultures. 
However, when SMCs were cocultured with ECs, the yields increased from ~ 14% within 
0-10 nM GSNO cases to a dramatic 51% within 100 nM GSNO additive cultures. Taken 
together, results show that 100 nM GSNO might help in the synthesis, release and 
deposition of hyaluronic acid by human aortic SMCs within biomimetic vascular 
coculture environment. Our future studies are designed to elucidate the molecular weight 
ranges of hyaluronic acid fragments synthesized and released under respective 
conditions. 
45 
 
 
Figure 3.3 When GSNO (0-100 nM) was supplemented to HA-SMC cultures, in the 
presence or absence of EC cocultures, elastin protein released into pooled media (A) or 
deposited within cell matrix (B), sulfated GAGs released into pooled media (C) or 
deposited within cell matrix (D), and HA released into pooled media (E) or deposited 
within cell matrix (F) was quantified. Data shown represent mean ± standard error of 
protein synthesis after 21 days of culture, normalized to cell count within respective cases 
(n = 6/ condition). * indicates p < 0.05 compared to GSNO-free cultures; # indicates p < 
0.01 for no cocultures vs. EC coculture, at a given GSNO dosage. 
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3.5. LOX enzyme activity 
LOX has been shown to play an important role in the crosslinking and maintenance of 
ECM proteins such as elastin and collagen, and thus expected to participate in ECM 
remodeling associated with cardiovascular diseases. However, LOX synthesis and 
activity within adult HA-SMC cultures has not been identified earlier. In this study, the 
LOX enzymatic activity was quantified within the cell matrix and pooled media to (a) 
establish the stand-alone and synergistic benefits of GSNO and EC cocultures to LOX 
activity, and (b) determine whether a correlation exists between LOX enzymatic activity 
and matrix protein yields within respective cultures. In the absence of EC cocultures and 
GSNO, LOX activity within pooled media from HA-SMC cultures was quite low (0.076 
± 0.002 nM on a per cell basis; Fig. 3.4 A). These basal levels were drastically increased 
by 10.6-, 12.3- and 20.9–fold, with the addition of 1, 10 and 100 nM GSNO, respectively 
(p < 0.001 for 0 nM vs. higher GSNO dosages; p < 0.001 for 1 nM vs. 100 nM; p < 0.001 
for 10 nM vs. 100 nM). In GSNO-free cultures, coculturing with ECs resulted in a 4.2-
fold increase in LOX activity within pooled media, compared to that within SMC cultures 
(p < 0.001). These levels were furthered by 3.9-, 6.2- and 34.8-fold, respectively, with the 
addition of 1, 10 and 100 nM GSNO to SMC-EC cocultures (p < 0.001 vs. controls in all 
the cases). 
The basal levels (at 0 nM GSNO) of LOX activity within cell matrix of SMC cultures 
(0.067 ± 0.014 nM) increased by 1.65-fold, 2.97-fold and 5.5-fold, respectively, with the 
addition of 1, 10 and 100 nM GSNO (Fig. 3.4 B; p < 0.01 for 0 nM vs. higher GSNO 
doses; p < 0.01 for 1 nM vs. higher GSNO doses; p < 0.01 for 10 nM vs. 100 nM). EC 
coculture provided no significant benefit to LOX activity within cell matrix, in the 
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absence of GSNO. Surprisingly, 1 and 10 nM GSNO inhibited LOX activity within cell 
matrices in the presence of EC cocultures, while 100 nM GSNO promoted a dramatic 
10.6-fold increase (p < 0.001 for 100 nM vs. lower dosages). This dramatic increase in 
LOX activity within cell matrix at 100 nM GSNO dosage, in the presence or absence of 
EC cocultures, partially explains the multi-fold increases in HA, elastin and sGAG 
deposition within HA-SMC cell matrices. The only other known report on the effects of 
NO on LOX synthesis showed a 4.5-fold increase in LOX mRNA expression within 
chick aortic SMC cultures, with the addition of 100 nM GSNO
74
. We hypothesize that the 
dramatic increases in LOX activity seen at 100 nM GSNO and EC cocultures in our study 
might be due to significant increase in LOX mRNA expression, which would be 
investigated in our future studies. 
 
Figure 3.4 LOX enzyme activity within pooled media (A) or within cell matrix (B), 
when GSNO (0-100 nM) was supplemented to HA-SMC cultures, in the presence or 
absence of HA-EC cocultures. Data shown represent mean ± standard error of LOX 
synthesis after 21 days of culture, normalized to cell count within respective cases (n = 6 
per condition). * indicates p < 0.05 compared to GSNO-free cultures; # indicates p < 0.01 
for no cocultures vs. EC coculture, at a given GSNO dosage. 
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3.6. Release of MMPs-2, 9 and TIMP 
In this study, the amounts of MMPs-2, 9 and TIMP into pooled media was quantified 
on a per cell basis (Fig. 3.5). The amounts of these enzymes were insignificant to be 
accurately quantifiable in cell matrix. In the absence of EC coculture and GSNO, HA-
SMCs released ~ 25 pg of MMP-2 on a per cell basis (Fig. 3.5 A). The addition of 1-100 
nM GSNO to SMC cultures suppressed MMP-2 release by 50-70% on a per cell basis (p 
< 0.01 for 0 nM vs. higher GSNO dosages; p < 0.01 for 1 nM vs. higher GSNO dosages). 
Coculturing with ECs suppressed MMP-2 release by SMCs, in the absence of GSNO. 
The average MMP-2 release within EC cocultures increased from 11.6 pg within controls 
(0 nM GSNO) to ~ 15 pg within 1 nM GSNO and to ~ 26 pg within 10 and 100 nM 
GSNO cultures (p < 0.01 for 0 nM vs. 10 or 100 nM GSNO, within cocultures). On the 
other hand, MMP-9 levels increased marginally within SMC cultures in the presence of 
GSNO, compared to GSNO-free cultures (Fig. 3.5 B; p < 0.01 for 0 nM vs. higher GSNO 
dosage; p < 0.01 for 1 nM vs. 100 nM; p < 0.01 for 10 nM vs. 100 nM). Within EC 
cocultures, MMP-9 levels were inhibited at lower GSNO concentrations (0-10 nM) 
compared to SMC cultures, although 100 nM GSNO increased MMP-9 release by SMCs 
for reasons not clear at this stage. 
In the absence of cocultures and GSNO, HA-SMCs produced 1.57 ± 0.39 pg of 
TIMP-1 on a per cell basis (Fig. 3.5 C). These TIMP-1 levels were significantly 
suppressed by addition of 1 nM GSNO (p < 0.01 for 1 nM vs. 0 nM GSNO), while 10 
and 100 nM GSNO offered only marginal benefits compared to controls. Within EC 
cocultures, although 1 nM GSNO did not enhance basal levels of TIMP-1 release by HA-
SMCs (3.05 ± 0.6 pg per cell; p = 0.22 for 1 nM vs. 0 nM), 10 and 100 nM GSNO 
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promoted 1.96-fold and 2.1-fold increases in TIMP-1 release into pooled media (p < 
0.001 vs. 0 nM GSNO in both cases; p < 0.001 vs. 1 nM GSNO in both the cases). In 
general, higher levels of TIMP-1 release were noted in cocultures compared to when 
SMCs cultured alone. Taken together, these results suggest that (a) exogenous GSNO 
supplementation suppressed MMP-2 and marginally enhanced MMP-9 release when HA-
SMCs were cultured alone, (b) MMPs levels increased within cocultures with increasing 
GSNO, and (c) higher GSNO dosages enhanced the release of TIMP-1 by HA-SMCs in 
the presence of HA-EC cocultures. 
Matrix metalloproteinases, specifically MMP-2 and MMP-9, play an important role in 
degrading basement membrane and ECM microenvironment, thus facilitating SMC 
migration during injury or disease (atherosclerosis, aneurysms, angioplasty, etc.) 
conditions in vasculature. On the other hand, naturally-available tissue inhibitors of 
MMPs (e.g., TIMP-1) released by SMCs contribute to reduction in such ECM 
breakdown, SMC migration and inflammation levels. Thus, a balance (or lack thereof) of 
these two components contributes to changes in SMC phenotype from quiescent to 
migratory and invasive nature. However, the specific levels of MMPs and TIMPs 
synthesized by adult human vascular SMCs within 3D biomimetic cultures are not 
known. Besides, very few studies explored the role of nitric oxide in regulating MMPs 
and TIMP levels within vasculature, under healthy or diseased conditions. In a recent 
study, Dey et al. reported on the molecular pathways involved in NO-mediated release  of 
MMPs and TIMP by rat aortic SMCs in vitro
114
. They noted that in the presence of 
DETA NONOate, an NO donor, rat SMCs synthesized and secreted more MMP-2 and 
less amounts of MMP-9, while TIMP-2 levels increased as well. We hypothesize that the 
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higher levels of MMPs and TIMP-1 noted within cocultures might be due to the 
combined release from SMCs and ECs, although further experiments are needed to 
quantify their release from ECs alone, and the effects of paracrine signaling between HA-
ECs and HA-SMCs. 
 
Figure 3.5 When GSNO (0-100 nM) was supplemented to HA-SMC cultures, in the 
presence or absence of EC cocultures, the release of MMP-2 (A), MMP-9 (B), and 
TIMP-1 (C) into pooled media was quantified. Data shown represent mean ± standard 
error of protein synthesis after 21 days of culture, normalized to cell count within 
respective cases (n = 3 per condition). * indicates p < 0.05 compared to GSNO-free 
cultures; # indicates p < 0.01 for no cocultures vs. EC coculture, at a given GSNO 
dosage. 
 
 
3.7. Immunofluorescence labeling of Elastin, Fibrillin and LOX 
Immunofluorescence images under these culture conditions qualitatively support the 
elastin and LOX deposition within cell matrix layers discussed above. When SMCs were 
cultured alone within 3D scaffolds (Fig. 3.6), significantly higher staining for matrix 
elastin was noted within cultures supplemented with 10 and 100 nM GSNO, compared to 
that at 0 and 1 nM GSNO. Similar increases in LOX deposition was noted within cultures 
receiving higher dosages of GSNO. Although coculturing with HA-ECs resulted in 
higher amounts of matrix elastin deposition at all GSNO dosages, the staining intensity 
was more pronounced at higher GSNO concentrations (10 and 100 nM; Fig. 3.7). In 
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strong agreement with quantitative data, a robust staining for LOX within 100 nM GSNO 
additive cultures was apparent, when SMCs were cocultured with ECs. Images from 
negative control cultures (stained without primary antibody) showed no coloration (data 
not shown). In general, staining for these proteins was evident in different planes of focus 
within these 3D gels. These data are in broad agreement with the quantitative data on 
matrix elastin (Fig. 3.3 B) and LOX activity (Fig. 3.4 B) within respective cultures. 
While staining for fibrillin expression could be seen within all the cases, it was modest 
and seems to be confined to the periphery of the cells. It also raises the possibility that 
adult human aortic SMCs do not produce much fibrillin, although further studies are 
needed to precisely measure the ability of HA-SMCs to synthesize and deposit protein 
fibers (fibrillin, fibulins, MAGPs, etc.) important for elastin assembly and maturation. 
Our current studies are geared towards elucidating the ultrastructure of the matrix 
proteins (e.g., fibrillar, co-localization), using characterization tools such as transmission 
electron microscopy. 
It could be seen that the combined amount of elastin and GAGs (quantified in Figs. 
3.3 and 3.4), in both pooled media and cell matrix, and is much lower than that quantified 
from BCA assay (Fig. 3.2). This suggests that in addition to elastin and GAGs, numerous 
other proteins such as collagens and proteoglycans, might be released and deposited by 
HA-SMCs within 3D scaffolds, which we intend to quantify in our future studies. 
Intuitively, we speculate that changing the composition or stiffness of the 3D scaffold (2 
mg/ml type-1 collagen) used in this study, might influence the cell proliferation and 
matrix synthesis outcomes by HA-SMCs in the presence of GSNO. Besides, results from 
this study pose a few challenging questions: Does exogenous GSNO addition stimulate 
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endogenous NO release by HA-ECs, and if so, is there a dose-dependency affect? At 100 
nM GSNO addition, what cytokines and chemokines are being released by SMCs and/or 
ECs, and are they influencing the multi-fold increases noted in protein release and matrix 
deposition? Our current studies are geared towards investigating these phenomena within 
our culture system. Nevertheless, a systematic understanding of the complex pathways 
involved in NO-mediated SMC signaling is essential in formulating pharmaceutical 
approaches for the treatment of vascular degenerative diseases. 
 
Figure 3.6 Immunofluorescence images of elastin, fibrillin and LOX proteins deposited 
by HA-SMCs within cell matrix layers, in the presence of GSNO (0-100 nM). HA-SMCs 
were cultured alone within 3D scaffolds, in the absence of cocultures with endothelial 
cells. 
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Figure 3.7 Immunofluorescence images of elastin, fibrillin and LOX proteins deposited 
by HA-SMCs within cell matrix layers, in the presence of GSNO (0-100 nM). HA-SMCs 
were cultured within 3D scaffolds, in the presence of cocultures with human aortic 
endothelial cells. 
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CHAPTER IV 
 
RESULTS AND DISCUSSION: ANEURYSMAL HUMAN SMCS IN 2D AND 3D 
CULTURES 
 
4.1. Aneurysmal HA-SMC proliferation 
For 2D and 3D cultures, we seeded at roughly 10,000 cells in each well, as measured 
by hemocytometer analysis.  However, we performed a quantitative cell density analysis 
on day 1 after seeding to accurately measure the number of cells seeded and for both 
cases ~7,800 cells were seeded in each case.  The proliferation of diseased HA-SMCs 
cultured in 2D and 3D, both in the presence and absence of GSNO is shown in Fig. 4.1.  
In the absence of GSNO the SMCs proliferated 2.8-fold in 2D, and roughly doubled in 
3D gels (p < 0.05 vs. 2D control) at 21 days cultured.  The addition of 100 nM GSNO 
decreased the SMC proliferation in both 2D and 3D to 2.05-fold (p < 0.05 vs. 2D control) 
and 1.3-fold (p < 0.05 vs. 2D control, p < 0.05 vs. 3D control) respectively.   
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Figure 4.1 (A) Fold increase in human aneurysmal SMC density within 3D cultures 
supplemented with GSNO (0-100 nM). Data shown represent mean ± standard error of 
cell count after 21 days of culture, normalized to initial seeding density (n = 3/ 
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 
2D vs. 3D, at a given GSNO dosage. 
 
It is also important to note that the GSNO dose used in this study was identified from 
our previous study (Chapter III) where a range of GSNO doses were tested to upregulate 
the ECM components.  Just like our past study, we did not investigate the NO activity 
and release rates from GSNO within culture media at neutral pH, as this data has been 
previously reported
94,95
.  Previous studies utilizing the aneurysmal SMCs show ~4.2 fold 
increase in cell proliferation under normal conditions in 2D
115
.  Alternately, in a study 
involving rat aneurysm SMCs proliferated 2.5± 0.32 fold over 21 days
116
.  The data 
obtained in this study was found to be between the results obtained in previous 
experiments in 2D and the absence of GSNO.  There is still no work that looks at the 
addition of GSNO in 3D cultures of aneurysmal SMCs and the data obtained in this 
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experiment shows a slight decrease in the proliferation of SMCs when compared to the 
data shown in Chapter III.   
 
4.2. Total protein synthesis by aneurysmal HA-SMCs 
The total protein amount synthesized by the diseased HA-SMCs, cultured in both 2D 
and 3D, under the presence or absence of GSNO is quantified in Fig. 4.2.  The total 
protein amounts were quantified as two separate components: released into the pooled 
spent media and the protein deposited in the cell matrix.  Diseased HA-SMCs synthesized 
and deposited 16.2 ± 2.4 ng and 266.4 ± 40 ng (p < 0.05 vs. 2D control) of protein, on a 
per cell basis, in 2D and 3D cultures respectively.  With the addition of GSNO there was 
a significant multi-fold increase in the total protein in the cell matrix in both the 2D and 
3D cultures, compared to cultures that lacked GSNO (p < 0.05 vs. 2D control and p < 
0.05 vs. 3D control).  Also, there was a significant difference between the total protein on 
a per cell basis that was deposited in the cell matrix between the 2D and 3D cultures in 
the presence of GSNO (p < 0.05 vs. GSNO-free controls in both 2D and 3D).  The total 
protein synthesized on a per cell basis and released into the pooled spent media in the 
absence of GSNO was 16.8 ± 2.5 µg and 37.9 ± 5.7 µg (p < 0.05 for 3D vs. 2D) 2D and 
3D cultures, respectively. Similar to that seen in the cell matrix, there was a significant 
increase in the total protein synthesized and released into the pooled spent media with the 
addition of GSNO: 34.6 ± 5.2 µg in 2D cultures and 52.7 ± 7.9 µg within 3D cultures, 
respectively (p < 0.05 vs. 2D control, p < 0.05 vs. 3D control and p < 0.05 vs. 2D with 
GSNO).      
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Figure 4.2 Total protein amounts deposited within cell matrix (A) or released into pooled 
media (B), when GSNO (0, 100 nM) was supplemented to human aneurysmal SMC 
cultures, in 2D and 3D cultures. Data shown represent mean ± standard error of protein 
synthesis after 21 days of culture, normalized to cell count within respective cases (n = 6/ 
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 
2D vs. 3D, at a given GSNO dosage. 
 
4.3. Elastin synthesis and deposition by aneurysmal HA-SMCs 
The total elastin synthesized by diseased HA-SMCs was quantified as that released 
into the pooled spent media (i.e., tropoelastin) or that deposited into the cell layers (i.e., 
matrix elastin).  The elastin deposited into the cell matrix was 0.56 ± 0.08 pg in 2D 
cultures, and 0.81 ± 0.12 pg within 3D cultures (p < 0.05 for 2D vs. 3D).  Upon addition 
of GSNO, two opposite trends were noticed.  The 2D cultures induced less matrix elastin 
in the cell layers than in the absence of GSNO (p < 0.05 vs. 2D control), while the 3D 
cultures promoted deposition of significantly higher matrix elastin amounts in the 
presence of GSNO (p < 0.05 vs. 3D control; p < 0.05 for 3D vs. 2D with GSNO).  The 
elastin deposited in the cell layers (i.e., matrix yield) is significantly lower compared to 
the elastin released into the pooled media.  Within GSNO-free controls, elastin released 
into the pooled media (tropoelastin) was 152.8 ± 22.9 pg in 2D and 169.23 ± 25.4 pg in 
A B
V 
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3D, which are not significantly different.  When GSNO was added, the 2D cultures did 
not have a significant change in the tropoelastin released, while there was a larger 
increase in the release of tropoelastin within 3D cultures (p < 0.05 vs. 3D control; p < 
0.05 for 3D vs. 2D with GSNO).   
From the data shown in Figs. 4.3 A and B, the matrix elastin yield (ratio of matrix 
elastin to the total elastin produced) within aneurysm HA-SMC cultures was calculated. 
When aneurysm SMCs were cultured in 2D, the matrix elastin yields were 0.4% and 
0.08% within 0 nM and 100 nM GSNO additive-cultures, respectively. However, 3D 
cultures modest enhanced matrix elastin yields, both in the presence or absence of 
GSNO. The matrix elastin yield within 0 nM and 100 nM GSNO additive cultures were 
0.5% and 0.8%, respectively.  
In this study we cultured human aneurysmal SMCs in both 3D collagen scaffolds and 
on collagen-coated 2D plastic plates.  The 3D cultures allow us to mimic physiological 
conditions and enable future tissue engineering based approaches for in situ elastin 
regeneration.  We noted an increase in tropoelastin production as well as matrix elastin 
deposition within 3D cultures under the presence of GSNO cocultures.  These results 
confirm our hypothesis that delivering exogenous NO cues to aneurysmal SMCs might 
help promote protein synthesis, release and deposition within 3D cultures, in addition to 
regulating their proliferation behavior.  Rat aneurysmal SMCs under the presence of 
different exogenously supplemented cues showed a 1 to 1.6 fold increase in the total 
amount of elastin compared to 2D culture controls
116
.  Similar results were observed in 
our 2D and 3D cultures with the 3D culture being similar to the largest increase observed 
in previous studies.  
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Figure 4.3 When GSNO (0, 100 nM) was supplemented to human aneurysmal SMC 
cultures, in 2D or 3D cultures, elastin protein released into pooled media (A) or deposited 
within cell matrix (B).  Data shown represent mean ± standard error of protein synthesis 
after 21 days of culture, normalized to cell count within respective cases (n = 6/ 
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 
2D vs. 3D, at a given GSNO dosage. 
 
4.4. Glycosaminoglycan synthesis by aneurysmal HA-SMCs 
Our past study (Chapter III) reported for the first time the dose-dependent effects of 
NO donors on the GAG synthesis by human aortic SMCs
117
.  The total sGAG 
synthesized by the diseased HA-SMCs, cultured in both 2D and 3D, under the presence 
or absence of GSNO is quantified in Fig. 4.4.  The sGAGs deposited into the cell matrix 
in the absence of GSNO is 0.14 ± 0.02 pg within 2D cultures, and 0.86 ± 0.13 pg within 
3D cultures (p < 0.05 vs. 2D control).  The addition of GSNO increased the deposition of 
sGAGs on a per cell basis in both the 2D and 3D cultures: 0.38 ± 0.06 pg (p < 0.05 vs. 
2D control) and 1.3 ± 0.2 pg (p < 0.05 vs. 3D control; p < 0.05 vs. 2D with GSNO), 
respectively.  Similar trends were seen in the sGAGs released into the pooled media, 
although the amounts were two orders of magnitude higher.  The sGAGs released into the 
B A 
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pooled media in the absence of GSNO is 15.8 ± 2.4 pg in 2D cultures, and 36.4 ± 5.5 pg 
within 3D cultures (p < 0.05 vs. 2D control).  The addition of GSNO increased the 
release of sGAGs on a per cell basis in both the 2D and 3D cultures: 34.4 ± 5.2 pg (p < 
0.05 vs. 2D control) and 62.9 ± 9.4 pg (p < 0.05 vs. 3D control and p < 0.05 vs. 2D with 
GSNO) respectively.   
From the data shown in Figs. 4.4 A and B, the matrix GAG yield (ratio of matrix 
GAG to the total GAG produced) within aneurysm HA-SMC cultures was calculated. 
When aneurysm SMCs were cultured in 2D, the matrix GAG yields were 0.9% and 2.3% 
within 0 nM and 100 nM GSNO additive-cultures, respectively. 3D cultures did not show 
any significant enhancement of matrix GAG yields, both in the presence or absence of 
GSNO. The matrix GAG yield within 0 nM and 100 nM GSNO additive cultures were 
1.1% and 2%, respectively. 
The release of non-sulfated GAGs (i.e., HA) synthesized by the diseased HA-SMCs, 
cultured in both 2D and 3D, under the presence or absence of GSNO is quantified in Fig. 
4.5.  HA deposited into the cell matrix in the absence of GSNO is 0.36 ± 0.05 pg in 2D 
cultures and 0.57 ± 0.08 pg in 3D cultures (p < 0.05 vs. 2D control).  The addition of 
GSNO modestly increased the deposition of HAs on a per cell basis in both the 2D and 
3D cultures: 0.51 ± 0.08 pg (p < 0.05 vs. 2D control) and 0.77 ± 0.11 pg (p < 0.05 vs. 3D 
control and p < 0.05 vs. 2D with GSNO) respectively.  Similar trends were seen in the 
HA released into the pooled media.  HA released into the pooled media in the absence of 
GSNO is 22.86 ± 3.4 pg within 2D cultures, and 27.66 ± 4.1 pg within 3D cultures, 
which are not significantly different.  The addition of GSNO increased the release of HA 
on a per cell basis in both 2D and 3D cultures: 29.75 ± 4.5 pg (p < 0.05 vs. 2D control) 
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and 40.71 ± 6.1 pg (p < 0.05 vs. 3D control and p < 0.05 vs. 2D with GSNO) 
respectively.   
From the data shown in Figs. 4.5 A and B, the matrix HA yield (ratio of matrix HA to 
the total HA produced) within aneurysm HA-SMC cultures was calculated. When 
aneurysm SMCs were cultured in 2D, the matrix HA yields were 1.6% and 1.7% within 0 
nM and 100 nM GSNO additive-cultures, respectively. However, 3D cultures modest 
enhanced matrix HA yields, both in the presence or absence of GSNO. The matrix HA 
yield within 0 nM and 100 nM GSNO additive cultures were 2% and 1.9%, respectively.  
 
 
Figure 4.4 When GSNO (0, 100 nM) was supplemented to human aneurysmal SMC 
cultures, in 2D or 3D cultures, sulfated GAGs released into pooled media (A) or 
deposited within cell matrix (B).  Data shown represent mean ± standard error of protein 
synthesis after 21 days of culture, normalized to cell count within respective cases (n = 6/ 
condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 
2D vs. 3D, at a given GSNO dosage. 
 
A B 
62 
 
 
Figure 4.5 When GSNO (0, 100 nM) was supplemented to human aneurysmal SMC 
cultures, in 2D or 3D cultures, HA released into pooled media (A) or deposited within 
cell matrix (B).  Data shown represent mean ± standard error of protein synthesis after 21 
days of culture, normalized to cell count within respective cases (n = 6/ condition). * 
indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 2D vs. 3D, at 
a given GSNO dosage. 
 
4.5. LOX- protein synthesis and activity 
The activity of LOX-proteins synthesized by aneurysmal HA-SMCs in both 2D and 
3D cultures can be seen in Fig. 4.6.  The LOX proteins deposited in the cell layers in the 
absence of GSNO were 0.025 ± 0.004 pM within 2D cultures and 0.11 ± 0.016 pM in 3D 
cultures (p < 0.001 for 3D vs. 2D).  While the addition of GSNO to 2D cultures did not 
induce a significant change in LOX activity within cell matrix, it induced ~2.5-fold 
increase in LOX activity within 3D cultures (p < 0.05 vs. 3D control; p < 0.0001 vs. 2D 
with GSNO).  When considering the LOX activity within pooled media under no 
exogenous GSNO addition, there was a large difference in the amounts quantified in 2D 
vs. 3D cultures: 0.185 ± 0.03 pM and 2.76 ± 0.4 pM (p < 0.05 vs. 2D control) 
respectively.  Surprisingly, the addition of GSNO to 3D cultures did not significantly 
A B 
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alter LOX activity, compared to GSNO absence. However, within 2D cultures, LOX 
activity increased multifold with the addition of GSNO (p < 0.001 vs. 2D control).  It is 
important to note that the LOX released into the pooled media in the 3D cultures was still 
significantly larger than the 2D cultures (p < 0.05 vs. 2D with GSNO).  Rat aneurysmal 
SMCs under the presence of different exogenously supplemented cues showed a 1 to 1.7 
fold increase in the total amount of LOX proteins compared to 2D culture controls
116
.  
Similar results were observed in our 3D cultures.  However, with ~12 fold increase the 
2D culture in this experiment shows a large upregulation of the LOX protein when under 
the influence of GSNO compared to other exogenously supplemented cues in the rat 
model.   
 
Figure 4.6 LOX enzyme activity within pooled media (A) or within cell matrix (B), 
when GSNO (0, 100 nM) was supplemented to human aneurysmal SMC cultures, in 2D 
and 3D cultures. Data shown represent mean ± standard error of LOX synthesis after 21 
days of culture, normalized to cell count within respective cases (n = 6 per condition). * 
indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 for 2D vs. 3D, at 
a given GSNO dosage. 
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4.6. MMPs-2, 9 and TIMP-1 protein synthesis 
The production of all MMPs and TIMPs for their release into the pooled spent media 
in 2D and 3D can be seen in Fig. 4.7.  The deposition of these proteins in the cell matrix 
was too low to be reported.  As for the MMP-2 release into the pooled media, the control 
levels quantified were not significantly different from each other in 2D (5.99 ± 0.9 pg) vs. 
3D (7.61 ± 1.1 pg) cultures.  With the addition of GSNO, although the 2D cultures did 
not induce any significant change, there was a significant increase in MMP-2 release 
within 3D cultures (p < 0.05 vs. 3D control; p < 0.05 vs. 2D with GSNO).  Similar trends 
were noted for MMP-9 release as well. Although no  significantly different values were 
noted within GSNO-free 2D and 3D cultures, the addition of GSNO induced a 
significantly higher increase in the release of MMP-9 within 3D cultures compared to the 
3D control (p < 0.05vs. 3D control).  TIMP-1 release into the pooled media was 
quantified at 0.53 ± 0.08 pg in 2D and 0.68 ± 0.1 pg in 3D cultures, in the absence of 
GSNO.  The addition of GSNO induced a significant increase in both the 2D and 3D 
cultures.  Within 2D cultures, it  increased to 0.71 ±  0.1 pg (p < 0.05 vs. 2D control), 
while within 3D cultures it increased to 1.82 ±  0.27 pg (p < 0.05 vs. 3D control and p < 
0.05 vs. 2D with GSNO).  Rat aneurysmal SMCs under the presence of different 
exogenously supplemented cues showed a 1.1 to 1.6 and 0.9 to 2 fold increase in the total 
amount of MMP-2 and MMP-9, respectively, compared to 2D culture controls
116
.  
Studies have shown that NO upregulated MMP enzymes in melanoma cell lines as well 
as in pulmonary tissue, and although the exact cause is still unknown it is believed that 
NO molecule or one of the partially reduced forms was responsible for that result
118,119
.  
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The addition of GSNO showed to follow the same trends as the hyaluronan oligomers 
and TGF-ß1 for both 2D and 3D cultures.    
 
Figure 4.7 When GSNO (0, 100 nM) was supplemented to human aneurysmal SMC 
cultures, in 2D and 3D cultures, the release of MMP-2 (A), MMP-9 (B), and TIMP-1 (C) 
into pooled media was quantified. Data shown represent mean ± standard error of protein 
synthesis after 21 days of culture, normalized to cell count within respective cases (n = 3 
per condition). * indicates p < 0.01 compared to GSNO-free cultures; # indicates p < 0.01 
for 2D vs. 3D, at a given GSNO dosage. 
 
4.7. Immunofluorescence labeling of Elastin, Fibrillin and LOX 
Immunofluorescence images under these culture conditions qualitatively support the 
elastin and LOX deposition within cell matrix layers discussed above. When aneurysmal 
SMCs were cultured alone within 3D scaffolds, significantly higher staining for matrix 
elastin was noted within cultures supplemented with 100 nM GSNO, compared to that at 
A B 
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0 nM GSNO and both 2D scaffold conditions (Fig. 4.8). Similar increases in LOX 
deposition was noted within 3D cultures receiving the dose of GSNO.  In strong 
agreement with quantitative data, a robust staining for LOX within 100 nM GSNO 
additive cultures was apparent, for both the 2D and 3D cultures. Images from negative 
control cultures (stained without primary antibody) showed no coloration (data not 
shown). In general, staining for these proteins was evident in different planes of focus 
within these 3D gels. These data are in broad agreement with the quantitative data on 
matrix elastin (Fig. 4.3) and LOX activity (Fig. 4.6) within respective cultures. While 
staining for fibrillin and LOX expression could be seen within all the cases, it was modest 
and seems to be confined to the periphery of the cells. It also raises the possibility that 
diseased adult human aortic SMCs do not produce much fibrillin or LOX, although 
further studies are needed to precisely measure the ability of HA-SMCs to synthesize and 
deposit protein fibers (fibrillin, fibulins, MAGPs, etc.) important for elastin assembly and 
maturation. 
It could be seen that the combined amount of elastin and GAGs (quantified in Figs. 
4.3 and 4.4), in both pooled media and cell matrix, and is much lower than that quantified 
from BCA assay (Fig. 4.2). This suggests that in addition to elastin and GAGs, numerous 
other proteins such as collagens and proteoglycans, might be released and deposited by 
HA-SMCs within 2D and 3D scaffolds, which we intend to quantify in our future studies.  
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Figure 4.8 Immunofluorescence images of elastin, fibrillin and LOX proteins deposited 
by HA-SMCs within cell matrix layers, in the presence of GSNO (0, 100 nM). HA-SMCs 
were cultured alone within 2D and 3D scaffolds. 
 
4.8. Dimension measurements of both aneurysmal and healthy SMC 
The dimensions of healthy and diseased SMCs within 2D cultures lacking any GSNO 
are shown in.  This data shows that in diseased conditions, the overall area and perimeter 
significantly increased when compared to the healthy condition.  It is important to note 
that these cells came from different donors which can lead to a difference in size among 
the cells.   
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Table 4.1 Summary of cell dimension measurements. 
Healthy Area (µm2) 
Perim. 
(µm) 
Diseased  Area (µm2) 
Perim. 
(µm) 
1 5395.892 517.88 1 6817.193 864.848 
2 3341.64 376.03 2 32128 1866.53 
3 4019.314 431.657 3 4449.49 574.567 
4 8869.18 668.517 4 6602.274 580.818 
5 3349.1 512.516 5 3270.119 442.134 
6 7125.839 689.759 6 3679.142 667.762 
Average 5350.160833 532.7265 Average 9491.03633 832.7765 
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Figure 4.9 Comparison of healthy (A) and aneurysmal (B) SMCs at 5× in T-25 flask
A 
B 
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CHAPTER V 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1. Healthy SMCs within cocultures 
This study is based on the hypothesis that robust synthesis, organization and 
maturation of elastin and GAGs within adult blood vessels could be accomplished, on 
demand, by exogenously delivering NO cues which proffer developmental signals and 
stimulate the intrinsic elastogenesis capability of adult human aortic SMCs. Accordingly, 
a novel biomimetic, 3D cellular engineering approach has been developed and tested to 
evaluate the stand-alone and synergistic effects of NO and EC cocultures on the synthesis 
and deposition of matrix proteins on demand, which has not been attempted earlier.  The 
following are the key conclusions from this study: 
 We have shown that in the cases of both HA-SMCs cultured alone and in 
cocultures with HA-ECs, there is a suppression of the HA-SMC proliferation as 
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the dose of GSNO increased.  This trend is not followed by the HA-EC cultures 
under the influence of GSNO. 
 GSNO also encouraged multi-fold increases in the total ECM protein synthesis 
deposited into the cell matrix as well as released into the pooled media, with the 
most upregulation occurring at the 100 nM dose of GSNO. 
 In general, addition of GSNO promoted increases in the ECM protein (elastin, 
GAGs, HA, and LOX) release as well as deposition into the cell matrix.   
 The benefits of GSNO further increased in the presence of HA-EC cocultures.   
 The matrix metalloproteinases that regulate the ECM protein of the vascular 
tissue and their inhibitors have also been affected by both the exogenously 
delivered GSNO and the HA-EC coculture.  For the most part these enzymes as 
well as their inhibitors increased in the presence of GSNO and even more so 
under coculture conditions except for MMP-2 in the absence of coculture. 
 Immunofluorescence labeling of both elastin and LOX qualitatively supports the 
deposition within cell matrices as quantified from biochemical assays.  The 
staining for fibrillin could be seen modestly in all the cases, and it was 
predominately confined to the periphery of the cells.  
5.2. Aneurysmal SMC in 2D and 3D cultures   
 The proliferation of diseased aneurysmal HA-SMCs was suppressed in the 
presence of 100 nM GSNO in both 2D and 3D cultures.   
 The total protein synthesized by the diseased cells (deposited and released into the 
pooled media) in both 2D and 3D cultures increased with the addition of 100 nM 
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GSNO.  Also there was a significant upregulation of protein synthesis in the 3D 
cultures compared to the 2D cultures. 
 The general trend of the specific ECM proteins studied (elastin, GAGs, HAs, and 
LOX) show a general upregulation in the presence of 100 nM GSNO.  The trends 
showed on average a significant larger protein synthesis in 3D cultures than the 
2D cultures. 
 With the addition of 100 nM GSNO, the release of MMP-2, 9, and TIMP-1 
showed a significant increase in the 2D cultures.  As for the 3D cultures, there 
was only a significant increase in the presence of GSNO for the MMP-2 and 
TIMP-1.  Finally, in the presence of GSNO, the values of MMP-2, 9, and TIMP-1 
in 3D cultures were significantly larger than their 2D counterparts.   
 Immunofluorescence labeling of both elastin and LOX qualitatively supports the 
deposition within cell matrices as previously discussed.  The staining for fibrillin 
could be seen modestly in all cases it was predominately confined to the periphery 
of the cells.  
 Overall the addition of GSNO significantly upregulates the ECM proteins 
necessary for homeostasis of diseased smooth muscle tissue.  The overall 
proliferation and protein creation is minimal when compared to that of healthy 
tissue, so either higher concentrations of GSNO are needed, or more treatment 
time is necessary to return normal function to diseased HA-SMCs.   
 The overall dimensions of the diseased cells in 2D were larger than the healthy 
SMCs, which can possibly explain the low amount of ECM release and deposition 
in the diseased assays when compared to the healthy experiments.   
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 ECM data obtained in aneurysm cell lines is much lower than the values obtained 
in healthy SMCs even though they follow similar trends. 
5.3. Recommendations  
 The following are recommendations for future studies to further understand the 
effects of both nitric oxide as well as other possible factors in synthesis and regulation of 
vascular smooth muscle tissue.   
 Test the role of fluid flow on cell behavior through a pulsatile pump attached to 
the described microfluidic device. 
 Investigate the role of ECM microenvironment on cell migration, proliferation 
and matrix remodeling. 
 Study the matrix synthesis and deposition by diseased adult human aortic smooth 
muscle cells within 3D biomimetic cocultures under the influence of nitric oxide.   
 Relevant drug and toxicology screening, tissue engineering and regenerative 
medicine therapies, as well as vascular disease remodeling in vivo. 
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